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Abstract
This international multidisciplinary document intends to provide clinicians with 
evidence- based practical patient- centered recommendations for evaluating patients 
and decedents with (aborted) sudden cardiac arrest and their families. The document 
includes a framework for the investigation of the family allowing steps to be taken, 
should an inherited condition be found, to minimize further events in affected relatives. 
Integral to the process is counseling of the patients and families, not only because of 
the emotionally charged subject, but because finding (or not finding) the cause of the 
arrest may influence management of family members. The formation of multidiscipli-
nary teams is essential to provide a complete service to the patients and their families, 
and the varied expertise of the writing committee was formulated to reflect this need. 
The document sections were divided up and drafted by the writing committee mem-
bers according to their expertise. The recommendations represent the consensus opin-
ion of the entire writing committee, graded by Class of Recommendation and Level of 
Evidence. The recommendations were opened for public comment and reviewed by the 
relevant scientific and clinical document committees of the Asia Pacific Heart Rhythm 
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Society (APHRS) and the Heart Rhythm Society (HRS); the document underwent ex-
ternal review and endorsement by the partner and collaborating societies. While the 
recommendations are for optimal care, it is recognized that not all resources will be 
available to all clinicians. Nevertheless, this document articulates the evaluation that 
the clinician should aspire to provide for patients with sudden cardiac arrest, decedents 
with sudden unexplained death, and their families.
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TOP 10 TAKE-  HOME MESSAGES
 1. Sudden cardiac death (SCD) is an important public health issue 
and warrants further study to better quantify its occurrence, 
its impact on society, and the opportunities for improving 
outcomes through public education and provision of automated 
external defibrillators and cardiopulmonary resuscitation (CPR) 
training.
 2. For survivors of sudden cardiac arrest (SCA), victims of sudden 
unexplained death (SUD), and their relatives, a multidisciplinary 
team is central to thorough investigation, so as to maximize the 
opportunity to make a diagnosis. Where there has been an SCD 
or resuscitated SCA and a genetic cause is suspected, genetic 
testing and counseling is essential for families, to ensure that 
risks, benefits, results, and the clinical significance of genetic 
testing can be discussed.
 3. The psychological care of families affected by SUD and survi-
vors of SCA (and their families) should run in parallel with the 
investigation process. Assessment by professionals trained in 
psychological care should be offered, as well as grief counseling 
and peer support, where appropriate.
 4. For the investigation of SUD, a detailed personal and family 
history is essential, with attention to sentinel symptoms during 
life such as syncope or seizures, witness accounts, premorbid 
investigations, and inspection of any cardiac rhythm monitoring 
around the time of death.
 5. A comprehensive autopsy is an essential part of the investiga-
tion of SUD and should include collection and storage of tis-
sue suitable for genetic analysis. When the autopsy suggests 
a possible genetic cause, or no cause and the heart is normal, 
referral to a multidisciplinary team for further investigation is 
indicated.
 6. For victims of SCD or survivors of cardiac arrest where the 
phenotype is known, genetic testing of the proband focused on 
likely candidate genes, along with clinical evaluation of family 
members, aids in identifying family members with, or at risk of 
developing, the same condition.
 7. For victims of SCD or survivors of cardiac arrest where the 
phenotype is not known, arrhythmia syndrome– focused ge-
netic testing may help arrive at a secure diagnosis, whereas 
wider testing without careful consideration of the implica-
tions of indeterminate results by experienced clinicians may 
only serve to add uncertainty and lead to misinterpretation of 
results.
 8. For the investigation of SCA survivors, essential inquiry includes 
detailed personal and family history, witness accounts, physical 
examination, multiple electrocardiograms (ECGs), and cardiac 
imaging. Ambulatory monitoring and/or provocative testing (ex-
ercise, pharmacological, and invasive electrophysiological) may 
provide additional useful information. A sample suitable for fu-
ture DNA testing should be taken early in the patient's course 
and stored.
 9. Genetic investigation of SCA survivors is best undertaken at 
a center with multidisciplinary care infrastructure and should 
focus on likely candidate genes known to be causally related 
to the suspected phenotype. In some cases, genetic evalua-
tion without a suspected phenotype may be undertaken with 
appropriate genetic counseling, although genetic evaluation 
of patients with a known nongenetic cause of cardiac arrest is 
discouraged.
 10. The investigation of the families of victims of SUD and survivors 
of SCA should include clinical and, if known, genetic cascade 
testing. If the cause of SUD (or rarely, SCA) is unknown, then 
clinical investigation of first- degree relatives may include physi-
cal examination, ECGs, cardiac imaging, ambulatory monitoring, 
and provocative testing (exercise, pharmacological, and rarely 
invasive electrophysiological) with multidisciplinary team super-
vision. Follow- up and periodic re- evaluation are important and 
are directed by initial findings.
1  | INTRODUC TION
1.1 | Purpose
This expert consensus statement represents an international 
multidisciplinary effort led by the Asia Pacific Heart Rhythm 
Society (APHRS), in partnership with the Heart Rhythm Society 
(HRS) and in collaboration with the Association for European 
Cardiovascular Pathology (AECVP), the European Heart Rhythm 
Association (EHRA), the European Society of Human Genetics 
(ESHG), the Latin American Heart Rhythm Society (LAHRS), 
the National Society of Genetic Counselors (NSGC) (USA), the 
Pediatric and Congenital Electrophysiology Society (PACES), and 
the European Reference Network for Rare and Low Prevalence 
Complex Diseases of the Heart: ERN GUARD- Heart. The intent is 
to provide clinicians with practical patient- centered recommen-
dations for evaluating patients with sudden cardiac arrest (SCA), 
decedents with sudden cardiac death (SCD), and their families, 
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based on all available evidence. Although the recommendations 
are for optimal care, the writing committee recognizes that not 
all resources will be available to all clinicians. Nevertheless, this 
document articulates the evaluation that the clinician should as-
pire to provide.
1.2 | Organization of the writing committee
The writing committee consisted of internationally recognized ex-
perts from 14 countries in the fields of cardiac electrophysiology, 
cardiology, pediatric cardiology, genetic counseling, community 
genetics and public health genomics, and cardiac pathology, rep-
resenting APHRS, HRS, AECVP, EHRA, ESHG, LAHRS, NSGC, 
PACES, and ERN GUARD- Heart and selected according to each 
society's procedures. In addition, a patient representative was cho-
sen to provide a consumer viewpoint. Each partner society nomi-
nated a chair, who did not have relevant relationships with industry 
and other entities (RWIs). In accordance with the APHRS policies, 
disclosure of any RWIs was required from the writing committee 
members (Appendix 1) and from the peer reviewers (Appendix 2); 
of the 28 committee members, 23 (82%) had no relevant RWIs. 
Recommendations were drafted by the writing committee members 
who did not have relevant RWIs.
1.3 | Methodology and evidence review
After development of a preliminary outline, committee members 
were given writing assignments and a schedule of conference calls. 
Writing committee members conducted a comprehensive evidence 
search using MEDLINE/PubMed, Embase, and the Cochrane Library 
and summarized the evidence in standardized tables (Appendix S1 
in Supporting Information), with attention to the study type, size, 
inclusion criteria, and key findings. The writing committee reviewed 
evidence and established consensus to generate recommendations, 
which are presented in a modular knowledge chunk format, with 
each chunk including a table of recommendations, a brief synopsis, 
recommendation- specific supportive text, flow diagrams or tables 
as appropriate, and references. Recommendations were formulated 
according to the American College of Cardiology (ACC)/American 
Heart Association (AHA) Class of Recommendation (COR) and Level 
of Evidence (LOE) system1 (Table 1) and were subject to a period of 
public comment. The COR indicates the strength of a recommenda-
tion based on assessment of the estimated benefits and risks; LOE 
rates the quality of evidence that supports the recommendation 
based on type, quantity, and consistency of data from clinical trials 
and other sources. Case reports were not used to support recom-
mendations. The threshold for consensus was considered as 80% or 
higher agreement. The 74 recommendations were balloted by the 28 
writing committee members and approved by an average of 94%. A 
quorum of two- thirds of the writing committee was met for all votes.
1.4 | Document review and approval
After review by the entire writing committee, the recommendations 
were opened for public comment; the draft document was reviewed 
by the International Scientific Document Writing Committee of the 
APHRS and the Scientific and Clinical Documents Committee of the 
HRS and was revised prior to external review. The document under-
went external peer review by reviewers appointed by the APHRS 
and HRS and each of the collaborating societies. After subsequent 
revisions and endorsement by the participating societies, the docu-
ment was ready for publication.
1.5 | Scope of the document
This document provides a framework for the investigation of (a) 
patients with SCA, (b) decedents with sudden unexplained death 
(SUD), and (c) families of both SCA survivors and SUD victims, 
as many conditions responsible for the cardiac arrest or unex-
plained death may be familial. Identifying a cause is important 
for preventing further events in the family, should an inherited 
condition be found. Integral to the process is the counseling of 
the patients and families, not only because of the emotionally 
charged subject, but because finding (or not finding) the cause 
of the arrest may influence the futures of the family members. 
The disciplines of cardiology, pediatrics, radiology, pathology, 
counseling, psychology, and genetics are all involved in this pro-
cess. Therefore, the formation of multidisciplinary teams is es-
sential to provide a complete service to the patients and their 
families.
While this document endeavors to provide clinicians with 
practical recommendations for evaluating patients with SCA, 
decedents with SUD, and their families, the best approach will 
vary with the situation and will be influenced by, for exam-
ple, the subject's age and results of initial testing. Although 
some of the recommendations do specify an age cutoff, it is 
recognized that this age is somewhat arbitrary and may not 
be always appropriate for the disease being investigated for 
or the demographics of the patient's country. Nevertheless, 
where an age is specified in a recommendation, it has passed 
the consensus voting of the writing group. Referral to a center 
with a multidisciplinary team experienced in such evaluations 
is recommended because it can facilitate navigation of these 
complexities. A multidisciplinary team can also help organize 
interval follow- up evaluations for SCA survivors and their fam-
ily members. Repeated interval follow- up can reveal important 
new clinical data and allows for integration of new knowledge 
into the continued evaluation and care of these patients. The 
writing committee members recognize that not all investigative 
modalities recommended will be available in all circumstances; 
however, this document is an attempt to outline an approach to 
which the clinician should aspire.
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1.6 | Relevant clinical practice documents
Table 2 lists pertinent guidelines and consensus statements that 
the writing committee considered for this document. The included 
documents contain relevant information for the diagnosis of patients 
with SCA and SCD.
1.7 | Definitions
The terms used in the consensus statement are defined in Table 3.
2  | EPIDEMIOLOGY
2.1 | Epidemiology: sudden death
"Sudden unexplained death" refers to an unexpected and sudden 
death in an individual older than 1 year. Sudden death occurring 
unexpectedly within the first year of life is termed “sudden unex-
plained death in infancy” (SUDI). Multiple definitions have been 
in use over the past decades, although most recent studies imple-
ment a definition that differs between witnessed and unwitnessed 
events; in witnessed cases, death has to occur within 1 hour of 
change in cardiovascular status, whereas unwitnessed cases have 
to be seen alive and functioning normally within 24 hours of being 
found dead.12,13
SCD constitutes the majority of SUD.14– 16 Reported overall 
SCD incidence rates vary across studies and countries, in part 
due to large difference in SCD definitions and methods for esti-
mation of SCD rates. Previous studies report overall SCD rates 
ranging from 15 to 159 SCD per 100 000 persons per annum, 
corresponding to 6%– 20% of all deaths.17– 24 However, both in-
cidence and causes of SCD vary markedly with age. Lowest 
SCD incidence is observed in children and adolescents.15,18,25– 28 
SCD incidence is low in children and the young under 35 years 
and increases dramatically up until the age of approximately 
60– 80 years.15,19,20,29,30
In young persons aged 1– 35 years, most SCDs are caused by 
potentially inherited heart diseases, including primary arrhythmo-
genic disorders (eg, congenital long QT syndrome and catecholami-
nergic polymorphic ventricular tachycardia [CPVT]), hypertrophic 
cardiomyopathy, arrhythmogenic cardiomyopathy, and dilated 
cardiomyopathy;15,18,25– 29,31,32 however, coronary artery disease, 
anomalous coronary arteries, aortic dissection, congenital heart 
disease, and myocarditis are also potential causes, potentially 
TA B L E  1   ACC/AHA recommendation system: Applying Class of Recommendation and Level of Evidence to clinical strategies, 
interventions, treatments, and diagnostic testing in patient care*
Reprinted with permission from the American College of Cardiology (ACC) and the American Heart Association (AHA).
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with a non- negligible genetic component (Figure 1). From the age 
of 35 years, coronary artery disease becomes the most common 
cause of SCD, although potentially inherited heart diseases remain 
a common cause of SCD at least until the age of 50 years.27,29,33 
Individuals with SUD who subsequently have negative pathologi-
cal and toxicological assessment may be assumed to have sudden 
arrhythmic death (syndrome), or SAD(S), a term synonymous with 
“autopsy- negative SUD.”
At any age, males have higher SCD rates compared with females, 
even after adjustment for risk factors of coronary heart disease.34 
Ethnic background seems to have large effect.35,36
Recommendations for improving outcomes from sudden death
COR LOE Recommendations References
1 B- NR 1. Investigation of SUD at a 
young age should be made a 
public health priority due to the 
combined prevalence of inherited 
cardiac diseases of at least 1:500, 
the years of potential life lost, 
and the significant impact on the 
family and community; therefore, 
public funding should be allocated 
for relevant investigations.
15,25,37
1 C- EO 2. Identification of inherited 
cardiac conditions that predispose 
to SCD should be made a public 
health priority, as diagnosis may 
prevent future cardiac events in 
affected family members.
1 B- NR 3. The burden of SUD and varied 
outcomes in relation to sex, 
different ethnic populations, 
and socioeconomic backgrounds 
should be investigated worldwide.
35,36,38,39
Synopsis
SUD is a tragedy and, in the case of an underlying genetic pre-
disposition, may be preventable. The main cause of SUD is SCD. 
SCD in the young often occurs in people who were thought to be 
well, may occur without warning symptoms, and is often the first 
presentation of an underlying genetic heart disease. Across all 
ages, estimates differ from 5% to 20% of all deaths, and ethnicity- 
specific data on SCD incidences worldwide are sparse. Cause of 
death changes according to age (Figure 1). Exact estimates of the 
burden of SCD are crucial in order to adjudicate public health 
spending.
Recommendation- specific supportive text
1. and 2. Inherited cardiac disorders are the main cause of SCD 
in the young. Sudden death is SCD in 60%–90% depending 
on age, of which the majority is potentially from inherited 
cardiac disease.2,15,40 Exact estimates of the burden of SCD 
are crucial in order to adjudicate public health spending.25
3. Estimates of SCD among different ethnic backgrounds are 
sparse worldwide.35,36,38,39
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Sudden cessation of cardiac activity with 




Death that occurs within 1 hour of onset of 
symptoms in witnessed cases, and within 





Unexplained sudden death occurring in an 




Unexplained sudden death occurring in 
an individual younger than 1 year with 
negative pathological and toxicological 
assessment
Note: Synonymous with “sudden 




Unexplained sudden death occurring in an 
individual older than 1 year with negative 
pathological and toxicological assessment
Note: Synonymous with “autopsy- negative 
sudden unexplained death”
Sudden unexplained 
death in epilepsy 
(SUDEP)
Sudden and unexpected, nontraumatic 
and nondrowning death of a person 
with epilepsy, without a toxicological or 
anatomical cause of death detected during 
the postmortem examination
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2.2 | Epidemiology: sudden cardiac arrest survivors
2.2.1 | Background
Out- of- hospital cardiac arrest (OHCA) is a leading cause of mor-
tality globally41– 43 and is defined as the loss of functional cardiac 
mechanical activity in association with an absence of systemic cir-
culation, occurring outside of a hospital setting. The exact burden 
of OHCA remains unknown, since a considerable number of cases 
are not attended by emergency medical services (EMS) and re-
gional variations are prevalent in both reporting systems and sur-
vival.17,44,45 Approximately 275 000 people in Europe have cardiac 
arrest treated by EMS per year, with only 29 000 (10.5%) surviving 
hospital discharge.46 In England, 28 729 EMS- treated OHCA cases 
were reported in 2014 (53 cases per 100 000 of the resident popula-
tion), with only 7.9% surviving to hospital discharge.47 In the United 
States, reports from 35 communities suggested an incidence of 55 
per 100 000 person- years48 or approximately 155 000 individuals 
having an EMS- treated all- rhythm OHCA per year.48 Globally, the 
weighted incidence estimates per 100 000 person- years of EMS- 
treated OHCA are 34.4 in Europe, 53.1 in North America, 59.4 in 
Asia, and 49.7 in Australia. For reported survival estimates, the 
percentage survival to discharge was 7.6% in Europe, 6.8% in North 
America, 3.0% in Asia, and 9.7% in Australia.42
Significant geographical variation in the incidence of OHCA as-
sociated with poor outcomes has remained unchanged in the past 3 
decades.17,41,42,44 However, implementation of coordinated efforts 
targeted at improving the local chain of survival in some cities has 
improved regional survival to 20%– 40%.49,50 This survival benefit 
can be partially attributed to varying definitions of OHCA,42 but it is 
primarily due to a coordinated effort to optimize the effectiveness 
of the local chain of survival.51 Identifying and improving weak links 
in the local chain of survival, paired with targeted approaches to im-
prove the effectiveness, has resulted in positive outcomes achieved 
in several geographic regions.49,52– 54
2.2.2 | Causes of out- of- hospital cardiac arrest
OHCA causes are classified into cardiac and noncardiac causes.47,55,56 
Approximately 80% of individuals presenting with OHCA reached by EMS, 
and in whom resuscitation is considered possible, have a cardiac cause.56
OHCA can affect seemingly fit and healthy athletes, young adults, 
or children. The incidence of SCD in athletes can range from 1 in 
F I G U R E  1   Distribution of causes of death among autopsied cases of sudden cardiac death (n = 753) according to age in persons aged 
1- 49 years in Denmark (J.T.- H., unpublished data). SADS, sudden arrhythmic death syndrome. *Coronary artery disease, especially in young 
persons, may be due to inherited disease (eg, familial hypercholesterolemia)
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23 000 to 1 in 200 000 athletes per year, depending on a number of 
factors including populations studied.57,58 In a retrospective analy-
sis of the Rescu Epistry database of consecutive OHCA attended by 
EMS in a specific area of Ontario, Canada, the incidence of SCD during 
participation in competitive sports was reported to be 0.76 cases per 
100 000 athlete- years.59 The main causes of SCD were stratified by 
age. In those younger than 35 years, structural heart and primary ar-
rhythmic causes were most common. In those aged between 35 and 
45 years, coronary artery disease was the most frequent underlying 
pathology.59 In a prospective study of children and young adults aged 
1– 35 years, 490 cases of SCD were identified from centers in Australia 
and New Zealand.25 The cause of death was unexplained in 40% of 
these cases at autopsy, in whom a structurally normal heart was re-
ported.25 In this study, the annual incidence of SCD was calculated to 
be 1.3 cases per 100 000 people. When stratified according to age 
group, the highest incidence (3.2 cases per 100 000 people per year) 
was observed in those aged 31– 35 years. Coronary artery disease was 
the most common cause ascribed. Younger age and SCD occurring at 
night were independently associated with unexplained SCD, probably 
due to congenital channelopathies. Less common causes were inher-
ited cardiomyopathies (eg, dilated, hypertrophic, and arrhythmogenic 
right ventricular), myocarditis, and aortic dissection.
The Cardiac Arrest Registry to Enhance Survival (CARES), 
established by the Centers for Disease Control and Prevention 
(CDC),60 evaluated OHCA events of presumed cardiac etiology 
that involve persons who received resuscitative effort. OHCA is 
defined in CARES as a cardiac arrest that occurred in the prehos-
pital setting, had a presumed cardiac etiology, and involved a per-
son who received resuscitative efforts, including cardiopulmonary 
resuscitation (CPR) or defibrillation. The registry includes 40 274 
OHCA records, of which 31 689 OHCA events were presumed to 
be of cardiac etiology (eg, myocardial infarction or arrhythmia) that 
received resuscitation efforts in the prehospital setting (mean age 
64.0 years [SD 18.2]; 61.1% male). The survival rate to hospital ad-
mission was 26.3%, and the overall survival rate from cardiac arrest 
to hospital discharge was 9.6% (Figure 2). Approximately 36.7% of 
OHCA events were witnessed by a bystander. Only 33.3% of all 
patients received bystander CPR, and only 3.7% were treated by 
bystanders with an automated external defibrillator (AED) before 
the arrival of EMS providers.
The group most likely to survive an OHCA is persons who are 
witnessed to collapse by a bystander and found in a shockable 
rhythm (ie, arrhythmias leading to ventricular fibrillation or pulseless 
ventricular tachycardia).60 Among this group, survival to discharge 
was 30.1% (Figure 3). A subgroup analysis, performed among per-
sons who experienced OHCA events unwitnessed by EMS, revealed 
that whites were significantly more likely to receive CPR than blacks, 
Hispanics, or members of other racial/ethnic populations (P < .001). 
Overall survival to hospital discharge of patients whose events were 
not witnessed by EMS personnel was 8.5%. Of these, patients who 
received bystander CPR had a significantly higher rate of overall sur-
vival (11.2%) than those who did not (7.0%) (P < .001).
Figure 4 shows bystander CPR and lay AED use by percentage 
of black residents in the area. Directing attention toward improving 
education, availability of AEDs, and treatment of cardiac arrest in 
predominantly black neighborhoods may save lives.39
Bystander AED use in OHCA in pediatric populations is variable 
and uncommon, with important variations based on neighborhood 
F I G U R E  2   Cumulative overall survival rates, by participating emergency medical services agency— Cardiac Arrest Registry to Enhance 
Survival (CARES), United States, October 1, 2005– December 31, 2010. Agencies sorted by total number of out- of- hospital cardiac arrest 
events in CARES (from low to high; range: 18– 5434)60
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characteristics leading to marked disparities in survival and out-
comes. Griffis et al38 reported that AED use (likely due to availabil-
ity) was more common in neighborhoods with a median household 
income of >$50 000 per year (12.3%; P = .016), <10% unemploy-
ment (12.1%; P = .002), and >80% high school education (11.8%; 
P = .002). Greater survival to hospital discharge and neurologically 
favorable survival were among arrests with bystander AED use, 
varying by neighborhood characteristics.
2.2.3 | Public health implications
The majority of persons who experience an OHCA event, irrespec-
tive of etiology, do not receive bystander CPR or other timely in-
terventions that are known to improve the likelihood of survival to 
hospital discharge (eg, defibrillation).54 Because nearly half of car-
diac arrest events are witnessed, efforts to increase survival rates 
should focus on timely and effective delivery of interventions by 
bystanders and EMS personnel (Figure 5).
Education of public officials and community members regarding 
the importance of increasing rates of bystander CPR and promot-
ing the use of early defibrillation by lay and professional rescuers is 
critical to increasing survival rates. Reporting at local and national 
levels can enable local and national public health and EMS agencies 
to coordinate their efforts to target improving emergency response 
for OHCA events, regardless of etiology, which can lead to improve-
ment in OHCA survival rates (Figure 6).
Recommendations for improving outcomes in SCA survivors
COR LOE Recommendations References
1 B- NR 1. Targeted CPR training should 
be widely implemented with 
particular emphasis on low- income 
communities, ethnic minorities, and 
middle- to low- income countries.
38,60F I G U R E  4   Bystander treatments of patients with out- of- 
hospital cardiac arrest before emergency medical services arrival 
among neighborhoods by percentage of black residents. Reprinted 
with permission from the American Medical Association.39 
AED, automated external defibrillator; CPR, cardiopulmonary 
resuscitation
F I G U R E  3   Cumulative Utstein survival rates (patients alive when arriving to hospital) by participating emergency medical services 
agency— Cardiac Arrest Registry to Enhance Survival (CARES), United States, October 1, 2005– December 31, 2010. Agencies sorted by 
total number of out- of- hospital cardiac arrest events in CARES (from low to high).60 †Utstein survival refers to survival to hospital discharge 
of persons whose cardiac arrest events were witnessed by a bystander and had an initial rhythm of ventricular fibrillation or pulseless 
ventricular tachycardia (range: 0– 598)
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Recommendations for improving outcomes in SCA survivors
COR LOE Recommendations References
1 B- NR 2. The burden of out- of- hospital 
SCA and varied outcomes in 
different ethnic populations and 
socioeconomic backgrounds should 
be investigated worldwide.
35,38,39
1 B- NR 3. Appropriately maintained AEDs 
should be readily available at 
schools, stadiums, public transport 
stations, casinos, etc, as well as 
venues where no other access to 
AEDs is available (eg, trains, ships, 
planes), with appropriate training 
of users.
62,63
F I G U R E  5   Bystander- witnessed arrest, bystander cardiopulmonary resuscitation (CPR), shockable heart rhythm as first recorded rhythm, 
and survival on arrival at the hospital, Denmark, 2001– 2010. Reprinted with permission from the American Medical Association54
F I G U R E  6   Examples of complimentary bystander 
cardiopulmonary resuscitation (CPR) programs. Reprinted with 
permission from Elsevier61
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Synopsis
OHCA remains a significant cause of mortality globally. 
Despite implementation of cardiac arrest protocols including CPR 
training and AEDs, only 33% of witnessed OHCA cases receive 
bystander CPR and less than 4% are defibrillated onsite. OHCA 
hospital discharge survival remains dismal at around 10% and has 
remained stagnant for the past 3 decades. Significant geographic 
variation in OHCA incidence and the role of social disparities 
merit further research. Public health campaigns promoting CPR 
training in at- risk communities and greater availability of AEDs 
are needed.
Recommendation- specific supportive text
1. Coordinated efforts targeted at improving the local chain of 
survival have improved regional survival.49,50 Targeted ap-
proaches to improve the effectiveness of CPR have resulted 
in positive outcomes.52– 54 The group most likely to survive 
an OHCA is persons who are witnessed to collapse by a 
bystander and found in a shockable rhythm, so widespread 
CPR training is recommended. Subgroup analysis has revealed 
that whites were significantly more likely to receive CPR than 
other racial/ethnic populations.60 AED use was more com-
mon in neighborhoods with high median household income, 
<10% unemployment, and >80% high school education.38 
Therefore, maximum benefit will be gained from targeting 
CPR training to groups of high socioeconomic need and 
ethnic minorities.
2. The burden of OHCA and the response of bystanders appears to 
vary according to ethnicity and socioeconomic status.35,38,39,60 
Further investigation of these findings may result in targeted ap-
proaches to maximize outcome from investment when aimed at 
these communities.
3. Availability of AEDs has been shown to improve survival.62– 64 
Therefore, as the majority of cardiac arrests are witnessed, 
AEDs at schools, stadiums, stations, etc, may be expected to in-
crease survival. Venues where delivery of AEDs by emergency 
services is unlikely (eg, trains, ships, planes) are of particular im-
portance. Appropriately maintained equipment and appropriate 
training of potential AED users are an essential component of 
this strategy.
3  | MULTIDISCIPLINARY TE AM
3.1 | Introduction
The investigation of SCD and resuscitated SCA requires input 
from a variety of different disciplines. The coordination and the 
communication between them mandate the formation of a multi-
disciplinary team. Numerous consensus statements agree on the 
importance of a dedicated combined cardiac genetic service in this 
setting.2,11,65– 67
3.2 | Key features of an effective 
multidisciplinary team
Certain key features can be identified in well- functioning multidiscipli-
nary teams across specialties. Nancarrow et al68 propose 10 key attrib-
utes including positive leadership and management, communication 
strategies and structures, appropriate resources, appropriate skill mix, 
and a supportive team climate with a focus on education of each other. 
There should be open communication and shared decision- making.
The detection of inherited heart conditions by pathologists and 
by hospital clinicians requires heightened awareness of their exis-
tence and a simple referral pathway to a multidisciplinary service 
with cardiac genetic expertise. Clinical experience shows that the 
appointment of a coordinator, as well as an enthusiastic team leader, 
is essential to facilitate this process, and regular meetings increase 
relevance and improve attendance69 (Figures 7 and 8).
3.3 | Defining which disciplines should be 
represented
The investigation of SUD is led by (forensic) pathology and the in-
vestigation of resuscitated SCA by pediatric or adult cardiology, 
with cardiac heart rhythm specialists and genetic cardiologists often 
being central. Clinical and molecular genetic specialists and genetic 
counselors are needed because of the significant role of molecular 
genetics in achieving a diagnosis and cascade screening, the consid-
eration of multisystem genetic syndromes, and the high prevalence 
of genetic variants of uncertain significance.70,71 The high levels of 
psychological morbidity among SCA survivors and family members 
of both SCA survivors and decedents mandates access to psychol-
ogy expertise,72– 74 and input into the multidisciplinary team helps 
keep this in focus.75 The presence of a specialist cardiac genetic 
nurse in the cardiology inpatient setting increases detection of in-
herited cardiac conditions following SCA.76 Other clinical special-
ists can be helpful and be drafted in for certain cases— neurologists, 
pediatricians, metabolic specialists, and intensivists, for example.
3.4 | Coordination across disciplines and 
other boundaries
The fact that the many disciplines may not be co- located high-
lights the importance of a coordinator to a multidisciplinary service. 
Co- location is not critical for effective collaboration, and non- co- 
location should not be an excuse for failed collaboration. A regional 
or institutional coordinator could be a nurse specialist, genetic coun-
selor, or other allied professional and is vital to facilitate team meet-
ings and communication between specialists and between centers, 
with primary care and across regions or between states and coun-
tries where necessary to facilitate family screening69,77 (Figure 7).
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3.5 | Links to other services
Links to other services as proposed in a recent scientific statement66 
and practiced by some centers already69 include connections to mo-
lecular genetic expertise, researchers, primary health providers, be-
tween regions, and to a cardiac genetic clinical registry to facilitate 
family screening and follow- up across traditional boundaries (Figure 8).
Clinical and genetic registries are generally voluntary and 
consent- based and have a research element. We do not consider that 
they are compulsory. However, in this setting they do have particular 
relevance because many cases remain unresolved after the initial in-
vestigation and families may find comfort in knowing that efforts to 
find a diagnosis continue. The multidisciplinary team also provides a 
mechanism to revisit family members if new findings appear in the 
wider family or if the pathogenicity of a genetic variant is redefined.
Recommendations for the role of a multidisciplinary team for 
investigation of SUD and SCA
COR LOE Recommendations References
1 B- NR 1. The investigation of SUD and 
SCD due to a potentially heritable 
condition should be overseen 
by a multidisciplinary team 
with, as a minimum, appropriate 
expertise in pediatric and/or 
adult cardiology, genetics, genetic 
counseling, and pathology.
78– 82
Recommendations for the role of a multidisciplinary team for 
investigation of SUD and SCA
COR LOE Recommendations References
1 B- NR 2. The investigation of a sudden 
cardiac arrest survivor where a 
heritable condition is possible 
should be overseen by a 
multidisciplinary team with, as a 
minimum, appropriate expertise 
in pediatric and/or adult 




The cardiac and genetic investigation of SUD and resuscitated 
SCA should be overseen by a multidisciplinary team with appropri-
ate expertise in this area. Recommendations include adequate re-
sourcing, a dedicated coordinator, strong leadership, and a mutually 
supportive team that meets regularly.
Recommendation- specific supportive text
1. For regions where coordinated cardiac genetic services exist 
that include the investigation of SUD, detection of inherited 
heart conditions is higher than in regions where they are 
not.78 Families prefer specialized clinics that combine co- located 
cardiac and genetic expertise and genetic counseling.79 Many 
such dedicated clinics internationally have led to the detection 
of inherited heart conditions following SCD and resuscitated 
SCA.80– 82 It is therefore logical that multidisciplinary teams 
F I G U R E  7   Referral flow for cardiac genetic investigation of sudden cardiac death (SCD) or resuscitated sudden cardiac arrest (SCA). 
MDT, multidisciplinary team
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should have links to such clinics. Continued productive dia-
logue among pathology, coronial, police, and cardiac genetic 
services is recommended to improve the quality and relevance 
of forensic pathologists’ reports.86
2. Genetic testing in this context leads to a significant proportion 
of both pathogenic and unclassified variants, and precise evalu-
ation of clinical phenotype is imperative for the correct assigna-
tion of such variants, so that a service that combines specialist 
cardiology and genetic expertise is essential.83,84 Specialized 
clinics that combine co- located cardiac and genetic expertise 
and genetic counseling are preferred,79 and such combined clin-
ics have a high detection of inherited cardiac conditions follow-
ing resuscitated SCA.82,85
4  | COUNSELING FAMILIES ,  THE 
BERE AVED AND THE NE ARLY BERE AVED
Genetic counseling is a process that aims to assist patients and their 
families to understand and adapt to the medical, psychosocial, and 
familial impact of inherited diseases.87,88 Genetic counseling goes 
beyond the discussion of genetic testing and is important for all 
patients with a genetic condition, at all stages of management.89 
Although genetic counseling may be performed by any number of 
health professionals, genetic counselors are specifically trained in 
this role and have grown to a large allied health workforce world-
wide.90,91 In some institutions, this role may be performed by a clini-
cal/medical geneticist, genetic nurse, or other appropriately trained 
specialist.
In the setting of SCD or resuscitated SCA where a genetic cause 
is suspected, the inclusion of genetic counselors in the multidisci-
plinary team is widely advocated. The role of the cardiac genetic 
counselor includes taking a detailed family history, investigating and 
confirming details such as postmortem reports, providing education 
and awareness, assisting in coordinating family clinical screening, 
and providing psychosocial support.74,92– 95 Throughout the process 
of genetic testing, genetic counselors provide important pre- and 
post- test genetic counseling, assist with interpretation of the results, 
help communicate this information to relatives, and assist with cas-
cade genetic testing75,93,96,97 (Table 4).
Where there are significant emotional difficulties (see Section 
5), the process of effectively conveying genetic information can 
be challenging.112 For families who have experienced a young 
SCD where a genetic cause is suspected, learning the potential 
F I G U R E  8   Participants in a cardiac genetic service. “Pathologists” includes forensic pathologists. Modified with permission from 
Elsevier69
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inheritance risk to family members and need for clinical screen-
ing can add an additional stressor at a time of intense grief. 
Furthermore, with the increasing availability of postmortem ge-
netic testing (see Sections 6.4 and 6.5), the need for complex ge-
netic discussions with families is more commonplace.113 Genetic 
counseling prior to and after genetic testing is important, partic-
ularly where genetic test results are not straightforward such as 
identification of variants of uncertain significance or in the event 
of a variant reclassification.100,102
There is wide acknowledgment that genetic counseling as a 
process should go beyond just provision of information.109,114 The 
psychosocial aspects of genetic counseling include psychological 
support, empathic listening, crisis intervention skills, knowledge of 
family dynamics, coping models, processes of grief, and adjustment 
to disease diagnoses, all of which align with the core competencies 
of genetic counseling accreditation.115,116 Attending to the psycho-
social needs, in addition to provision of education and information, 
has been demonstrated to positively impact patient outcomes, 
largely based around knowledge and recall, but healthy adjustment, 
empowerment, behavioral change, and satisfaction with decision- 
making also reduce anxiety and worry.109– 111,115
Recommendations for counseling families affected by SUD and SCA
COR LOE Recommendations References
1 B- NR 1. Genetic counseling is strongly 
recommended for all families 
where there has been an SUD 
or resuscitated SCA and a 
heritable cause is suspected, 
and should include antemortem 
and postmortem data collection 
and evaluation, so that risks, 
benefits, results, and the clinical 




1 C- EO 2. It is recommended that genetic 
testing in families where an SUD 
or resuscitated SCA due to a 
heritable cause is suspected is 
performed only with appropriate 
genetic counseling.
Synopsis
Genetic counseling of patients and their families with genetic 
conditions is recommended, including those with SCD or resuscitated 
TA B L E  4   Key goals of genetic counseling following sudden cardiac death/resuscitated sudden cardiac arrest
Goal Description
Genetic counseling about 
inheritance risks
Provide information tailored specifically to the family about their inheritance risks.
Provide education and 
awareness
Educate about inheritance risks, the need for clinical surveillance, and options for genetic testing to allow the 
family to make subsequent important medical decisions. Conveying information is not straightforward, given 
varying health literacy and competing health concerns; however, genetic counseling can support effective 
communication.98 Genetic counseling can also include connection of families with advocacy organizations 
and relevant research studies.
Pre- and post- test genetic 
counseling
Explain the process and discuss the options of genetic testing, all possible outcomes of testing, implications 
for patients and/or their family members, and worries and fears about testing; ensure consideration 
of all possible results and implications.99 Care should be taken in conveying test results of uncertain 
significance,100,101 specifically ensuring adequate understanding and confidence to communicate key risk 
information to family members.
Pre- and post- test genetic 
counseling for cascade testing 
of asymptomatic relatives
There are ethical, legal, and social implications when considering cascade genetic testing of asymptomatic 
at- risk relatives. Careful pre- test genetic counseling should explore the individual's feelings toward their risk, 
how they might feel if they are gene positive or gene negative, and implications for their own health and 
clinical management based on their genetic result. Discussion about the potential for reclassification of the 
genetic result is also important.102,103
Provide input regarding 
classification of genetic 
variants
Knowledge of variant and gene curation processes will enable review of any genetic test findings at all stages 
of family management.104 Clinicians involved in family management (including genetic counselors) are more 
likely to provide conservative variant classifications compared to clinical laboratories,105 and processes to 
guarantee regular review of variants will ensure appropriate reclassifications are made.106,107
Obtain detailed three- 
generation family history and 
confirm details
Record family history information in a pedigree and interpret the information and the risk posed to family 
members. Taking a detailed family history can allow development of rapport, elucidate family relationships 
and social circumstances, and inform clinical care.108
Assist with coordination of 
family clinical screening
Ensure adequate understanding of the clinical screening recommendations for family members and provide 
assistance with communicating this to relatives as needed. Provide support in organizing cardiology 
appointments with appropriate tests.92
Provide psychosocial support 
and identify when referral to 
clinical psychologist is required
Although genetic counseling is unlikely to resolve any significant psychopathologies, the process of providing 
information and a big picture perspective allowing a patient to normalize their experience and emotional 
response can have a positive impact, including patient empowerment.109– 111
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SCA where a genetic cause is suspected. Key aspects of the process 
include discussion of inheritance risks, education and awareness, 
pre- and post- test genetic counseling, interpretation of genetic re-
sults, taking a family history, coordination of clinical screening, and 
psychosocial support. Genetic counseling is focused on both infor-
mation provision and psychosocial support and together has been 
shown to improve knowledge and recall; promote healthy adjust-
ment, empowerment, and behavioral change; increase satisfaction 
with decision- making; and reduce anxiety and worry. While genetic 
counseling is a process often performed by a variety of health pro-
fessionals, ideally a specifically trained genetic counselor or genetic 
nurse with appropriate skills in information provision and psychoso-
cial support would perform this role.
Recommendation- specific supportive text
1. Genetic counseling includes both information provision and 
psychosocial support. It is ideally performed by health pro-
fessionals with specific training and experience; this includes 
genetic counselors, genetic nurses, or other qualified health 
professionals.80– 82,84,85,99,109– 111
2. In the context of genetic testing, pre- and post- test genetic coun-
seling must be performed.75,95,96,113 In cases where there is uncer-
tainty in the findings, such as a variant of uncertain significance or 
a variant reclassification, this is of particular importance.100,102
5  | PSYCHOLOGIC AL C ARE
SCD where a genetic cause is suspected has a profound psycho-
logical impact on the surviving members of the family. Grief is a 
normal emotional response to the loss of a loved one. Individuals 
will grieve differently, and while there is no single trajectory, many 
will experience disbelief, yearning, anger, sadness, and accept-
ance.117 After a death, an individual will not return to normal, but 
rather create a revised meaningful life without the deceased. In a 
small proportion of bereaved individuals, the initial grief response 
does not resolve and may result in prolonged grief, or persistent 
complex bereavement disorder according to the Diagnostic and 
Statistical Manual of Mental Disorders, 5th Edition (DSM- 5).118,119 
This occurs in approximately 7% of the general bereaved popula-
tion,120 and in 21% of first- degree relatives following SCD in the 
young.121 Posttraumatic stress symptoms can also be experienced 
by family members. Posttraumatic stress occurs in response to a 
specific trigger, typically one that threatens one's own or a loved 
one's well- being. It is characterized by avoidance with hypera-
rousal and intrusive thoughts, including persistent and extreme 
fear and panic similar to that experienced by family members at 
the time of the event.122 Posttraumatic stress has been shown in 
44% of first- degree relatives following a young SCD.121 Individuals 
with prolonged grief and/or posttraumatic stress symptoms can 
benefit from intervention with a clinical psychologist or other ap-
propriately trained clinicians, and there is extensive evidence to 
support the efficacy of psychological treatments for these condi-
tions in other settings.120 Further, there is greater risk of other 
psychiatric comorbidities,118 suicide,123 and development of 
chronic medical conditions.124
Factors associated with poor psychological outcomes have been 
investigated. One study showed that mothers of the deceased were 
more likely to report anxiety and depression symptoms.72 In total, 53% 
of the mothers surveyed reported probable anxiety disorder on aver-
age 4 years after the death. In a larger study, after adjusting for factors 
including relationship to the decedent, those family members who wit-
nessed the death or discovered the decedent's body had a 3- fold risk of 
posttraumatic stress symptoms (OR 3.3, 95% CI 1.2– 8.7, P = .02) and 
a 4- fold risk of prolonged grief (OR 4.0, 95% CI 1.3– 12.5, P = .02).121 
Given that half report symptoms indicating psychological difficulties, 
all first- degree relatives should be offered psychological evaluation and 
treatment. Although the evidence for psychological support is derived 
from studies investigating SCD where a genetic cause is suspected, it 
may logically apply to those individuals who have survived SCA and their 
families (Figure 9).
There may be initial reluctance to seek psychological support 
given community stigma around mental health. Indeed, a recent 
study investigating families who had experienced a young SCD 
found that only 12% had sought psychological support, with most 
of those being self- referrals.125 In discussing options for ongoing 
psychological support with patients and families, normalizing their 
response to a significant psychological stressor and describing com-
mon symptoms of prolonged grief and posttraumatic stress may re-
duce any perceived sense of stigma and increase interest in seeking 
support.
A recent needs analysis of parents who had experienced the 
SCD of their child (including adult children) found that while medical 
F I G U R E  9   Psychological care 
following a sudden cardiac arrest (SCA) 
or a sudden unexplained death (SUD) 
where a genetic cause is suspected. 
Colors correspond to the Class of 
Recommendation in Table 1
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information and support were the most important need, psycholog-
ical information and support were the most unmet need.126 Nearly 
three- quarters reported wanting access to professional counseling 
or psychological services. Further, many indicated access to genetic 
testing or understanding the genetic cause to be an important need, 
highlighting the importance of maintaining realistic expectations re-
garding the diagnostic yield of postmortem genetic testing with fam-
ilies.100 At present, this is likely not greater than 15%, and there is a 
high likelihood of uncertain genetic findings especially with increas-
ing gene panel sizes.25,70 A Swedish study of parents whose children 
died suddenly between 15 and 35 years of age likewise showed a crit-
ical lack of information and support in the acute grief stage.127 This 
included a need for better communication of the postmortem exam-
ination process (how long it would take, when they would get results), 
time with a health professional to discuss the death, and information 
about the cause of death. There was a lack of psychological support 
in the immediate aftermath, with many family members seeking their 
own care, including grief counselors and support groups. The need 
for support in the early aftermath has been shown to be important in 
other studies examining suddenly bereaved parents.128,129
Community or peer- based bereavement support groups can 
also enhance social support.120,130 Peer support programs come in 
many different forms but always involve people with similar back-
grounds providing emotional, social, or practical support to each 
other.131 Peer supporters draw on their shared experiences to pro-
vide empathic understanding, information, and advice to those they 
are helping. A key aim is to promote hope, recovery from illness or 
trauma, improved life skills, psychological well- being, and social in-
tegration.132 A recent systematic review of peer support services for 
bereaved survivors of the sudden death of a loved one in multiple 
settings found evidence of reductions in grief and increased well- 
being and personal growth among participants, and improved per-
sonal growth and positive meaning in life among peer providers.133 
There is a current gap in care in addressing psychological support 
needs of families after the SCD of a young relative.
Recommendations for psychological care
COR LOE Recommendations References
1 B- NR 1. In the investigation of SCA 
where a genetic cause is 
suspected, it is recommended that 
referral be offered for assessment 
by a health professional trained 
in psychological evaluation 
and treatment to the patient (if 
survived) and immediate family 
members.
72,121,126,134
2a C- LD 2. In the investigation of 
SUD where a genetic cause 
is suspected, provision of 
information and referral to 
support services such as support 
workers, grief counseling, and 




The psychological impact to the family following an SCD where a 
genetic cause is suspected can be significant. Although many family 
members will navigate their way through this traumatic experience, 
up to 44% may require additional psychological support from an ap-
propriately trained health professional such as a clinical psycholo-
gist. Addressing community stigma around mental health needs to 
be considered and discussed with families. In addition, support ser-
vices such as social workers, grief counselors, psychosocial teams, 
and peer support groups may be useful to many families. Whereas 
the evidence for psychological support is derived from studies in-
vestigating SCD where a genetic cause is suspected, it may logically 
apply in those families where there has been an SCA.
Recommendation- specific supportive text
1. and 2. A clinical psychologist or appropriately trained health 
professional includes those equipped to assess and treat trauma; 
for example, those experienced in delivering cognitive behavioral 
therapies. While the evidence to date supports a need for psycho-
logical support in family members following a young SCD where 
a genetic cause is suspected, this may likewise be important for 
relatives of a patient who suffers an SCA.72,121,134 There is a 
need to train personnel in psychological care for SUD and SCA, 
as this is an area where the need is not currently met.
6  | INVESTIGATION OF SUDDEN DE ATH
6.1 | Investigation of sudden death: history— 
personal and family
Despite being “low- tech” and inexpensive, the history, as a tool for 
clinical phenotyping, is the essential and fundamental basis of ap-
proaching a patient with SCA because it can guide appropriate use and 
interpretation of other diagnostic modalities. The history should be fo-
cused toward both the decedent proband and also the wider family for 
evidence of other potentially affected members prior to investigations. 
Surviving family members should be investigated by a multidisciplinary 
team within a specialist program for cardiovascular genetic disorders 
with the all appropriate medical, genetic, and psychological personnel 
and ability for comprehensive investigations2,10 (Figure 10).
The proband age may help define potential etiologies; CPVT and 
long QT syndrome are typically diseases of the young, whereas cor-
onary artery disease and cardiomyopathies become more common 
with age (Figure 1). Although most deaths occur at rest or during 
sleep,25 death during exertion may point to specific etiologies such 
as CPVT, long QT syndrome type 1, or arrhythmogenic cardiomyop-
athy. In addition to a detailed prior medical and medication history 
(including potential drugs of abuse), the decedent's health in the 24– 
48 hours preceding death including the presence of any viral pro-
drome or fever, as well as any prescribed medication, may be relevant. 
Myocarditis secondary to viral infection may be associated with viral 
and gastrointestinal symptoms, and both Brugada syndrome and long 
QT syndrome may be exacerbated by specific pharmacological agents 
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through further inhibition of ion channel function.135 Fever is a well- 
recognized trigger of ECG changes and arrhythmia in Brugada syn-
drome136 and in some long QT syndrome subtypes,137 and in young 
children may be misdiagnosed as febrile seizures.138
Between 18% and 45% of sudden death cases may have expe-
rienced prior relevant symptoms, typically palpitations, chest pain, 
pre- syncope, or syncope, and may have undergone relevant inves-
tigations.29,70,139 All medical records relevant to the sudden death 
etiology should be sought.
Relevant information from the family history should be collected 
by a health professional with specific experience in cardiovascular ge-
netic disease (preferably a genetic counselor) and by an appropriately 
trained cardiologist. Symptoms and diagnoses in other family mem-
bers as well as prior cardiovascular investigations should be sought. 
Noncardiac findings may be highly pertinent including unexplained 
epilepsy unresponsive to conventional therapy; skeletal muscle weak-
ness; curled hair and subtle palmoplantar hyperkeratosis/kerato-
derma (arrhythmogenic cardiomyopathy)140; attention deficit disorder 
and intellectual disability (CPVT)141; and history of pneumothoraces, 
vascular disease, and gastrointestinal and uterine rupture (vascular 
Ehlers- Danlos syndrome).142 Any other deaths or major cardiac events 
in the family should be recorded including those related to drowning 
in good swimmers, unexplained motor vehicle accidents, and sudden 
infant death or late fetal demise. If the SUD was observed, it is useful 
to collect witness accounts about the events occurring immediately 
prior to the collapse and during any resuscitation attempts.
Recommendations for investigation of sudden death: personal and 
family history
COR LOE Recommendations References
1 B- NR 1. In the investigation of SUD, an 
effort should be taken to obtain 
detailed personal and three- 
generation family history (as a 
minimum) with the assistance of a 





1 B- NR 2. In the investigation of SUD, 
prior medical records and 
relevant investigations from the 
decedent proband and family 





The personal medical and three- generation family history pro-
vides the initial information on which subsequent investigations will 
be based. Specific features within the wider family may suggest diag-
noses and help direct subsequent investigation. The history should 
be recorded by cardiologists, specialist nurses, and geneticists or 
genetic counselors experienced in cardiovascular genetic diseases, 
ideally within the confines of a multidisciplinary program that can 
address the medical, genetic, and psychological needs of the family 
(see Section 3).
F I G U R E  1 0   Investigation of sudden 
unexplained death: personal and family 
history. Colors correspond to the Class of 
Recommendation in Table 1. SCD, sudden 
cardiac death
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Recommendation- specific supportive text
1. The personal and three- generation family history may provide 
critical information relevant to the etiology of SCD and provide 
a starting point for further investigations in both the decedent 
proband and surviving family members.77 Multiple studies show 
a significant proportion of children and adults experience rele-
vant cardiac symptoms prior to sudden death,10,25,29,70,135,138,139 
and some may have sought medical attention and undergone 
investigations. Available ECGs and cardiac imaging, together 
with autopsy findings, may allow a diagnosis to be made (or 
excluded) in the proband who, until family investigations have 
been performed, is the one definitively affected member of the 
family. Noncardiac features and symptoms may also provide 
important diagnostic information.140– 142
2. Further investigation is necessary where sudden death occurs in 
specific circumstances such as when a cardiac event may have 
triggered an apparently environmental death. Examples include 
road traffic accidents with no apparent cause and drowning in 
competent swimmers.
The presence and associated investigations for other noncar-
diac conditions should also be evaluated, specifically epilepsy. 
Failure to identify a neurological etiology or abnormality would 
suggest seizures may have had a cardiac etiology. Overlap syn-
dromes exist between true neurological epilepsy and long QT 
syndrome type 2.146,147
6.2 | Investigation of sudden death: examination of 
premorbid investigations
Individuals who have succumbed to SUD may have had pertinent 
investigations prior to their death that aid in the diagnosis of the 
cause of their SUD. Twelve- lead electrocardiogram (ECG) is the 
most useful pre- SUD investigation. Although long or short QT 
interval, spontaneous type 1 Brugada pattern, and early repolari-
zation pattern are associated with fatal arrhythmias due to con-
genital long QT syndrome, short QT syndrome, Brugada syndrome, 
or early repolarization syndrome,148– 152 many patients with SUD 
without structural heart disease have a normal or near- normal 
ECG,145,153 particularly women.154 Additional ECG findings sug-
gestive of arrhythmic syncope include bifascicular block; intraven-
tricular conduction abnormalities (QRS duration >0.12 s); Mobitz I 
second- degree atrioventricular block and first- degree atrioventric-
ular block with markedly prolonged PR interval; sinus bradycardia 
(<40 bpm) or slow atrial fibrillation (<40 bpm); nonsustained ven-
tricular tachycardia; pre- excited QRS complexes; negative T waves 
in right precordial leads or epsilon waves; and left ventricular hy-
pertrophy,5 any of which may indicate potential diagnoses of inher-
ited arrhythmia syndromes such as progressive cardiac conduction 
defect, familial pre- excitation, arrhythmogenic cardiomyopathy, 
or hypertrophic cardiomyopathy.4,151 In the general population, 
premature ventricular complexes (PVCs) are mostly benign; how-
ever, some frequent or complex PVCs significantly increase the 
risk of SCD.155– 157 If an ECG is recorded by the AED or EMS just 
before SCD, features such as J- wave or ST segment elevation (es-
pecially if augmented after a long pause) may help in the diagno-
sis of coronary spasm, early repolarization syndrome, or Brugada 
syndrome.158,159 Interpretation of ECGs obtained immediately after 
resuscitation/defibrillation should be performed with great caution 
(see Section 7.4).
Syncope is a sentinel clinical symptom before SUD and may prompt 
investigations subsequently useful in making a retrospective diagnosis 
of the cause of SUD. In particular, the trigger for the syncopal event 
bears useful information. Ambulatory ECG monitoring during life may 
provide clues to the cause of SUD and should be sought.
If transthoracic echocardiography, cardiac computed tomog-
raphy (CT), or cardiac magnetic resonance imaging (CMR) are 
performed during the patient's life, detailed review may indicate 
features of dilated cardiomyopathy, hypertrophic cardiomyopa-
thy, or arrhythmogenic cardiomyopathy.160 If blood or other tissue 
sample has been taken before SUD, this may be a source of DNA 
for genetic testing, should there not be a postmortem collection of 
tissue.8,11,67,151 Neurological findings such as developmental delay 
or seizures thought to be suspicious for epilepsy during life may 
contribute to a diagnosis of a cardiac channelopathy, such as CPVT 
or long QT syndrome.141,161,162 If a patient with SUD has a cardio-
vascular implantable electronic device (CIED) implanted, postmor-
tem interrogation of the CIED is useful to determine the cause and 
timing of SCD.163
Recommendations for investigation of sudden death: examination of 
premorbid investigations
COR LOE Recommendations References
1 B- NR 1. All relevant cardiac investigations, 
including 12- lead ECGs, 
echocardiography, CT, CMR, 
genetic analyses, and ambulatory 
monitoring recorded before SUD, 
should be reviewed and analyzed.
145,148– 150,
153– 158,164
1 B- NR 2. Any blood or DNA sample (eg, 
blood in EDTA, blood on filter paper 
card) taken before SUD should be 
stored for future genetic analysis.
84,165– 167
1 B- NR 3. Neurological events such as 
seizures suspicious for epilepsy 
before SUD should be reviewed 




2b C- LD 4. ECG information from the AED 
or ECG monitor recorded around 
the time of SCD may be useful for 
review and analysis.
158,170
1 B- NR 5. Any implanted cardiac electronic 
device in an individual with SCD 
should be reviewed and analyzed.
163,171,172
Synopsis
During the investigation of SUD, pertinent investigations per-
formed prior to death can aid in establishing the cause. Although 
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ECG features such as QT interval, type 1 Brugada pattern, and 
early repolarization may be critical for diagnosis, many ECGs taken 
during life will be normal. Ambulatory ECG monitoring and cardiac 
imaging should be sought to provide clues to the diagnosis of SCD. 
Symptoms attributed to a neurological cause may be re- evaluated, in 
collaboration with neurologists. Any potential DNA sample before 
SUD should be stored if tissue is not gained at autopsy. ECG informa-
tion from the AED, emergency services, or CIEDs may also be useful 
to determine the cause of SCD.
Recommendation- specific supportive text
1. Investigations during life may provide clues to the cause of 
SUD and should be sought to aid in diagnosis.173 These include 
resting, exercise and ambulatory ECG tracings, and cardiac imag-
ing studies (echocardiography, CT, and CMR).145,148– 150,153– 158,164
2. Samples for potential DNA testing taken during life may subse-
quently prove invaluable should they be the only source of DNA. 
Although it is a Class 1 recommendation that patients with SUD 
have an autopsy and material for DNA testing collected (see 
Section 6.3), it is recognized that sometimes this is not done, 
making blood or tissue samples taken during life the only remain-
ing source for molecular autopsy.84,165– 167 Using such samples 
requires appropriate consent from family, unless ordered by the 
coroner. It should be recognized that success varies depending 
on the storage method, but attempts to gather useful DNA may 
be worthwhile even from suboptimal sources. Future extraction 
methods may improve the yield so continued storage is advisable.
3. Symptoms such as seizures thought to be suspicious for epilepsy 
during life may in fact be attributable to a cardiac channelopathy 
when further investigation is done. Other neurological findings 
such as developmental delay hold significance for diagnoses such 
as CPVT. Thus, meticulous recording of neurological events dur-
ing life may lead to a diagnosis in SUD.70,146,147,161,162,168,169
4. Recordings from emergency services continuous ECG monitor-
ing or from interrogation of AEDs, when available, may provide 
clues to the etiology of SUD. However, it should be acknowl-
edged that a finding of ventricular fibrillation is often due to 
this rhythm being a final common rhythm in arrhythmic death, 
regardless of the initial rhythm causing hemodynamic collapse. 
Nevertheless, at points such as reinitiation of arrhythmia and 
glimpses of normal rhythm in between arrhythmia may suggest 
a specific diagnosis.158,170
5. The memory function of CIEDs may reveal the initiation pattern 
of cardiac arrhythmia and aid in the diagnosis of SCD. Therefore, 
if an SUD victim has a CIED implanted in life, interrogation of this 
device can provide useful clues in the diagnosis of SCD.163,171,172
6.3 | Investigation of sudden death: the postmortem 
examination and imaging
The critical components to the investigation of SUD include examining 
the circumstances of the death and the autopsy (Figure 11). Identification 
of SUD relies on the reporting of EMS, police, hospitals, and witnesses. 
Investigation of a death is determined by the jurisdiction in which the 
death occurs.14,174,175 Unexpected or unexplained deaths, when the in-
dividual was in apparent good health, should be carried out by a trained 
pathologist who has a thorough knowledge of cardiac pathology.176 
Autopsies vary not only by country but also by individual jurisdictions 
within countries. The autopsy should be comprehensive, examining 
all organs and conducted in a systematic and objective method with a 
focus on standardized reporting.2,67,177,178 Cases should be referred to a 
cardiac pathologist when a cardiac cause is suspected.2,176
Imaging includes X- rays and photography. Photography is useful 
in providing documentation of syndromic features and highlighting 
individual organ pathology. Postmortem CT and magnetic resonance 
imaging (MRI) have been shown to be useful179 but are not universally 
available. Noncardiac causes should be looked for including infection, 
thromboembolism, tumors, intracerebral lesions, respiratory disease, 
and abdominal causes such as ruptured abdominal aneurysm. Body 
mass index should be recorded along with waist circumference.
Ancillary testing should be performed including microbiology/
cultures for infectious disease, metabolic screening (particularly 
in younger children), toxicology, vitreous testing for biochemistry, 
genetic testing (see Sections 6.4 and 6.5), and other testing as in-
dicated by the autopsy findings. Taking a sample for toxicology is 
recommended in all sudden unexpected deaths.180
Samples for genetic testing should be saved at the time of au-
topsy from every sudden death case.2,181 Ideally, two of the follow-
ing three should be saved: a small piece of fresh frozen heart, a small 
piece of fresh frozen spleen/liver/thymus, and EDTA blood. If RNAlater 
(ThermoFisher Scientific, Waltham, MA, USA) or similar reagent to pre-
serve DNA at room temperature is available, fresh tissue can be trans-
ported in this to the referral genetic center without need for freezing.
The heart should be examined thoroughly67 and at least 7– 10 sam-
ples taken for histology. Cardiovascular disease is the leading cause 
of sudden death in the young and is divided into two major groups: 
morphologically positive (eg, congenital heart disease, coronary 
artery disease, and cardiomyopathy) and morphologically normal 
hearts. Combined with negative toxicology, those with morpholog-
ically normal hearts have been labeled as having “autopsy- negative 
sudden unexplained death” or “sudden arrhythmic death (syndrome) 
or SAD(S).”182 Samples should always be taken, even from a macro-
scopically normal heart, as histology may reveal inflammation and 
cardiomyopathies. Always consider sudden unexpected death in 
epilepsy (SUDEP) and sudden death in alcohol misuse (SUDAM)183 
where clinical history and circumstances are important. Pathologists 
and clinicians should not overinterpret findings in the heart at au-
topsy such as nonsignificant coronary artery disease, etc.184
Recommendations for investigation of sudden death: the 
postmortem examination and imaging
COR LOE Recommendations References
1 B- NR 1. An autopsy is strongly 
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Recommendations for investigation of sudden death: the 
postmortem examination and imaging
COR LOE Recommendations References
1 B- NR 2. Autopsies for SUD should 
be comprehensive, including 
photography, imaging, 
toxicology, gross examination 
of all organs, and detailed 
examination of the brain, heart, 
and thorax, with histology being 
essential.
14,175– 177,180
Recommendations for investigation of sudden death: the 
postmortem examination and imaging
COR LOE Recommendations References
1 B- NR 3. EDTA blood and/or one type of 
fresh tissue (heart, liver, spleen, 
skeletal muscle) should be saved 
at autopsy for SUD and banked 
at −20°C or −80°C for potential 
genetic analysis; two sources are 
ideal, if possible.
25,70,166,185
F I G U R E  11   Investigation of sudden unexplained death: the postmortem examination and imaging. Colors correspond to the Class of 
Recommendation in Table 1
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Recommendations for investigation of sudden death: the 
postmortem examination and imaging
COR LOE Recommendations References
2b C- LD 4. Storing frozen myocardial tissue 
may be considered at autopsy for 
SUD, as it may aid in assessing 
the significance of future genetic 
findings.
186,187
1 C- EO 5. Findings of an autopsy for 
SUD should be communicated 
to the family in a timely fashion 
in accordance with local legal 
requirements.
1 B- NR 6. Cases with likely cardiac causes 
for SUD should be referred to 
a pathologist with expertise in 
cardiac disease, as the finding of 
an abnormal or normal heart is 
important for family screening.
176,177,184
1 C- LD 7. When an autopsy for SUD 
reveals a possible genetic cause, 
or the heart is normal, then 
referral for clinical and genetic 





A comprehensive autopsy is an essential part of the investigation 
of SUD and should include collection and storage of tissue suitable 
for genetic analysis. When the autopsy suggests a possible genetic 
cause, or no cause and the heart is normal, referral to a multidisci-
plinary team for further investigation is indicated (see Section 3).
Recommendation- specific supportive text
1. SUD should have an autopsy done by a trained pathologist.174– 176 
Studies have shown that autopsies performed by pathologists 
who have a thorough knowledge of cardiac pathology have a 
superior diagnostic yield.174– 176 In cases where autopsy is not 
possible (eg, for religious reasons), a full body MRI or CT scan 
is recommended.179
2. Samples should be taken for infection and toxicology. 
Histological sampling of all important organs especially the 
heart (from multiple sites) is essential even when macroscopi-
cally normal.174,175
3. Blood or tissue suitable for DNA extraction and postmortem ge-
netic testing should be obtained at all autopsies.176 Following the 
initial investigation, DNA should be extracted and banked if ge-
netic disease is suspected or if the cause remains unknown.2,176 
Ideally, lack of cost coverage should not be a reason not to comply 
with these recommendations.
4. Frozen myocardial tissue may be useful for subsequent RNA anal-
ysis or expression studies of aberrant proteins.2,67
5. Cause of death should be discussed in a multidisciplinary meet-
ing (see Section 3) and provided by a pathologist to the medical 
examiner/coroner. The findings and follow- up recommendations 
should be communicated to the family.178,190,191
6. Finding of an abnormal or normal heart is important for family 
screening and directs much of the subsequent investigation (see 
Sections 6.4 and 6.5).
7. Autopsy phenotype should be established at a multidisciplinary 
meeting of pathologist, medical examiner, cardiologist, and clini-
cal geneticist.
6.4 | Investigation of sudden death: genetic 
evaluation where the phenotype is known
Genetic evaluation may be appropriate following SCD in two scenar-
ios: most commonly, where the deceased individual is the proband 
with no prior medical history, or alternatively the deceased is part of 
a family where diagnosis is established but he/she has not yet under-
gone genetic evaluation. Initially, pathological examination should be 
performed by an experienced pathologist to ensure that all cardiac 
and extracardiac features relevant to the potential diagnosis are rec-
ognized (see Section 6.3).
In cases where the deceased is the proband and a postmor-
tem diagnosis is established, identification of a pathological vari-
ant may facilitate genetic testing in the wider family evaluation. 
Genetic testing of DNA from the deceased proband may be per-
formed directly after autopsy or deferred until first- degree fam-
ily members have been clinically evaluated (Figure 12). As part of 
familial evaluation, a three- generation pedigree (at a minimum) 
performed by a practitioner knowledgeable in the genetics of car-
diovascular disease (eg, a genetic counselor or specialist nurse) is 
mandatory and should cover all potentially relevant cardiac and 
extracardiac features within the family (see Section 6.1). Genetic 
testing of deceased individuals may not be covered by health in-
surance in certain countries; in this instance, using a clinically af-
fected family member as the testing proband with confirmatory 
testing in the deceased may be a more feasible strategy. Clinical 
and genetic testing in the proband and multiple family members 
will define segregation of the identified genetic variant(s), adding 
to the validity of the genetic findings. The yield of genetic testing 
in cases where a diagnosis of cardiomyopathy is established post-
mortem is significantly greater than where structural changes are 
uncertain.192
In cases where no other family members are clinically affected 
and the deceased proband is an apparently isolated case, genetic 
testing can be used as evaluation of the single definitely affected 
individual within the family. Families should be counseled about 
the expected benefits and potential outcomes of genetic investi-
gations prior to testing. If identified variants are considered likely 
pathogenic or pathogenic, cascade testing across the family can be 
considered to identify at- risk individuals with no current clinical 
features.
In cases where the deceased is part of a family with a prior di-
agnosis of cardiovascular disease and known pathological variant, 
confirmatory genetic testing may be performed.
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Recommendations for investigation of sudden death: genetic 
evaluation where the phenotype is known
COR LOE Recommendations References
1 B- NR 1. For SCD where the phenotype 
is suspected to be heritable, 
genetic testing is recommended 
to attempt to elucidate the 
genetic basis and to facilitate 
the identification of first- degree 
family members at risk for 




1 C- LD 2. Genetic testing in the deceased 
proband with SCD and known 
phenotype should include only 
genes with robust evidence of 
gene– disease association.
192
1 B- NR 3. In first- degree relatives of 
a proband with SCD from a 
suspected heritable cause, 
phenotype- guided clinical 
screening is recommended and, 
where a genetic diagnosis is 




Recommendations for investigation of sudden death: genetic 
evaluation where the phenotype is known
COR LOE Recommendations References
1 B- NR 4. In families affected by SCD 
who have undergone genetic 
testing, periodic re- evaluation 
of the genetic test results is 
recommended.
106,194– 201
1 C- LD 5. A genetic diagnosis made in a 
relative of a proband with SCD 
should be considered together 
with the clinical findings.
70,143,189
Synopsis
A postmortem diagnosis following SCD significantly facilitates 
further clinical evaluation of family members and may provide an ex-
planation for the family as to the underlying etiology. Genetic testing 
targeted toward the clinical diagnosis and phenotype is an important 
component of the overall evaluation of both the proband and family 
and provides additional support to the clinical diagnosis. Further in-
vestigations can be performed as clinically indicated. In cases where 
no other individuals within the family are clinically affected, identifi-
cation of a definitively pathogenic variant in the proband facilitates 
cascade genetic testing in family members.
F I G U R E  1 2   Clinical and genetic 
evaluation after sudden death where a 
phenotype is known. Colors correspond to 
the Class of Recommendation in Table 1. 
*See Section 8.2
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Recommendation- specific supportive text
1. Genetic testing in the decedent proband is recommended to 
support the clinical diagnosis and facilitate cascade genetic 
testing within the family.10,11 The yield of genetic testing is 
significantly higher when associated with a specific postmortem 
diagnosis.84,192
2. If a cardiac phenotype has been identified in the deceased 
proband, genetic testing should be targeted toward that specific 
phenotype to maximize the chances of a clinically actionable 
result and minimize the risk of ambiguous secondary findings. 
Targeted panels for cardiomyopathy, channelopathies, familial 
thoracic aortic aneurysm, and familial hyperlipidemia are the pre-
ferred option. However, given the limited availability of proband 
DNA and potential financial implications, broader genetic test-
ing including whole exome and genome with selective reporting 
based on the phenotype may be considered. Robust evidence for 
gene– disease association is currently probably only available in 
the Clinical Genome Resource (ClinGen) expert panels for long 
QT syndrome, Brugada syndrome, hypertrophic cardiomyopa-
thy, arrhythmogenic cardiomyopathy.195,196,202 Wider panels and 
whole- exome sequencing/whole- genome sequencing share the 
potential disadvantage of a high burden of variants of uncertain/
unknown significance, but in experienced hands (ie, expert cent-
ers), this will not lead to unintended follow- up.203
3. Clinical evaluation for family members of a proband with an evi-
dent or likely phenotype can be targeted based on that pheno-
type, although due to varied expressivity and overlap syndromes 
should be sufficiently broad to provide a comprehensive cardio-
vascular evaluation. If a pathogenic or likely pathogenic variant 
has been identified in the deceased proband in a gene consistent 
with the clinical diagnosis, genetic counseling and testing should 
be offered to family members.25,80– 82,84,85,143,189,193 Cascade test-
ing for likely pathogenic variants should be done at the discretion 
of an experienced provider after reviewing the data. In cases with 
limited supporting data from the family, a more conservative ap-
proach may be appropriate.
4. Serial re- evaluation of variants should be performed based on 
new phenotype data in the family pedigree, or new data regard-
ing both specific variants and whole genes, the pathogenicity of 
which may have been up- or downgraded based on contempo-
raneous evidence.106,194– 196,204 Responsibility for re- evaluation is 
unclear, but the re- evaluation is best carried out in a center of 
expertise.
5. Genetic variants identified in deceased probands and subse-
quently in family members should be correlated with clinical find-
ings to determine segregation patterns within the family.
6.5 | Investigation of sudden death: genetic 
evaluation where the phenotype is unknown
SCD may occur in an individual without any prior medical history 
or medical data. As indicated above, a three- generation pedigree 
including examination of all potentially relevant cardiac and extra-
cardiac features within the family should be performed by a car-
diologist experienced in genetic heart disease or clinical geneticist 
experienced in cardiology in an effort to optimize the identifica-
tion of subtle clinical features before defining the cause of death 
as unknown. Specific triggers (eg, competitive athlete, emotional 
or physical stress, drug use, swimming, acoustic triggers, seizure) 
leading to the SCD event may help focus clinical and genetic inves-
tigation. Collection of blood and/or suitable tissue for molecular 
autopsy/postmortem genetic testing is recommended in all victims 
of SUD.2,10 Local protocols are recommended to ensure proper han-
dling and extended storage of biosamples, as well as processes and 
consent allowing for contact of families for genetic testing in the 
future.
Family members of sudden death victims where the phenotype 
remains unknown should be instructed to request re- evaluation of 
the index event in case of future developments in the family. Clinical 
signs or symptoms in first- degree family members leading to a sus-
pected phenotype of a sudden death victim may occur over many 
years and sometimes skip generations, so an unknown phenotype 
might prompt more extensive questioning of older family members.
In an SCD case where the phenotype remains unknown after ex-
pert evaluation, re- evaluation of family members to assess for new 
information that may impact diagnosis should be performed period-
ically, although the yield is low.205 We suggest every 3 to 5 years, 
but shorter intervals should be considered if there is more than one 
SCD event in the family. Periodic re- evaluation should be stopped 
for individuals after age 45 years, unless the decedent died in this 
age range or new findings emerge.
Three scenarios may trigger arrhythmia syndrome– focused ge-
netic evaluation of SCD even if the phenotype remains unknown: 
(a) documented arrhythmic death suggestive of an arrhythmia syn-
drome; (b) specific triggers associated with familial arrhythmia syn-
dromes; (c) young age (<40 years) (Figure 13).
Families should be counseled about the expected benefits and po-
tential outcomes of genetic investigations prior to testing. When ge-
notyping is performed, the identification of a genetic variant as causal 
remains challenging and requires reassessing the correct classification 
or potential reclassification periodically. With rapidly advancing geno-
typing technologies and the availability of large gene panels, the identi-
fication of genetic variants of uncertain/unknown significance becomes 
more frequent. Medical uncertainty in general elicits a variety of re-
sponses from patients. It is important to consider patients’ responses to 
the ambiguous nature of genetic testing. Medical professionals ordering 
genetic testing should be prepared for the possibility of their patients’ 
misinterpretation of such results. Pre- test counseling should include a 
discussion of the possibility of a variant of uncertain significance and 
what it would mean for the patient's care and its potential psychoso-
cial impacts. When a variant of uncertain significance is found, post- 
test counseling should include additional education and a discussion of 
the variant's implications and medical management recommendations 
based on the results. If identified variants are considered likely patho-
genic or pathogenic, cascade testing across the family should be offered 
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to identify at- risk individuals with no current clinical features. Cascade 
testing should not be performed with variants of uncertain significance; 
however, careful investigation within a multidisciplinary team (including 
genetic counseling) may allow eventual reclassification of the variant so 
that it may then be used for cascade testing (see Sections 3 and 4).
Recommendations for investigation of sudden death: genetic 
evaluation where the phenotype is unknown
COR LOE Recommendations References
1 B- NR 1. In an SUD case at a young age where 
the phenotype remains unknown after 
expert evaluation, re- evaluation of 
first- degree relatives to assess for new 
information that may achieve diagnosis 
should be performed every 3 to 5 years 
(shorter intervals should be considered 
if there is more than one SCD event in 
the family) until at least age 45 years.
25,70,80,85,
205,206
1 B- NR 2. In an SUD case where the 
phenotype is unknown, arrhythmia 
syndrome– focused genetic testing 
is recommended if 1) documented 
arrhythmic death is suggestive of an 
arrhythmia syndrome, and 2) SCD is 
preceded by specific triggers associated 
with familial arrhythmia syndromes.
25,70,80,84,85,
185,205– 208
2a B- NR 3. In an SUD case occurring in a 
patient younger than 40 years 
where the phenotype is unknown, 
arrhythmia syndrome– focused 




Recommendations for investigation of sudden death: genetic 
evaluation where the phenotype is unknown
COR LOE Recommendations References
3: No 
Benefit
B- NR 4. In an SUD case where the 
phenotype is unknown, hypothesis- 
free genetic testing using exome or 
genome sequencing is not indicated 
in routine patient care, as this may 
lead to misinterpretation of genetic 




Collection and storage of blood and/or suitable tissue for post-
mortem genetic testing is recommended in all victims of SUD. In 
a large number of cases, the phenotype underlying SCD remains 
unknown despite comprehensive evaluation of the victim and 
their family. In SCD cases where the phenotype is determined as 
unknown after expert evaluation, re- evaluation should be per-
formed periodically to assess for new information that may impact 
diagnosis. While hypothesis- free genetic testing is not indicated in 
cases of SCD where the phenotype remains unknown, arrhythmia 
syndrome– focused genetic evaluation of SCD is advised if (a) an ar-
rhythmic death is documented suggestive of an inherited arrhythmia 
syndrome, (b) specific triggers associated with familial arrhythmia 
preceded the SCD, and/or (c) SCD occurred at young age.
Recommendation- specific supportive text
1. Genetic diseases may express with reduced penetrance. Hence, a 
negative clinical screening does not exclude the (silent) presence 
of a genetic disorder. It is, therefore, reasonable to suggest 
F I G U R E  1 3   Investigation of sudden death: genetic evaluation where the phenotype is unknown. Colors correspond to the Class of 
Recommendation in Table 1. SCD, sudden cardiac death
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repeated screening with a time interval between 3 to 5 years 
until at least age 45 years. Studies demonstrating the yield of 
clinical screening after the sudden death of a close relative 
usually report only the result of the first screening.25,70,80,85,205,206 
Responsibility for the repeated (infrequent) screening lies in 
the hands of the individual, but the local team should make 
sure that he/she is appropriately informed.
2. In an SCD case where the phenotype is unknown, arrhythmia 
syndrome– focused genetic testing of the proband should be con-
sidered if (a) documented arrhythmic death (such as torsades de 
pointes arrhythmias leading to ventricular fibrillation) is suggestive 
of an arrhythmia syndrome, and/or (b) SCD is preceded by specific 
triggers (eg, competitive athlete, emotional or physical stress, swim-
ming, drug use, acoustic triggers, seizure) associated with familial 
arrhythmia syndromes.10,25,70,80,85,205,206,212 Collection and stor-
age of blood and/or suitable tissue for postmortem genetic testing 
is recommended in all victims of SUD irrespective of an identified 
phenotype at the time of death. Long- term storage of biosamples of 
SCD victims is recommended in expert centers to allow for genetic 
testing if indicated at present or in the future.10,25,70,80,85,205,206,212
3. In an SCD case where the phenotype is unknown, arrhythmia 
syndrome– focused genetic testing of the proband can be con-
sidered if SCD occurred at young age. Testing for cardiomyopa-
thy genes (such as LMNA) has been studied and can increase the 
 diagnostic rate, although it should be recognized that the yield is 
lower.10,25,70,80,85,205,206,212
4. Hypothesis- free genetic testing is not indicated in cases of 
SCD where the phenotype remains unknown. Genetic test-
ing using any range from large unfocused gene panels to 
whole- exome or whole- genome sequencing in the absence 
of a clinical phenotype or diagnosis may be considered in the 
context of a scientific effort but is not recommended for rou-
tine patient care and counseling.213,214 The aim of discourag-
ing hypothesis- free testing in clinical settings is to reduce the 
misinterpretation of genetic variants and their causality, spe-
cifically, variants of uncertain significance. A specific problem 
in this field is the nonuniformity in calling variants across dif-
ferent laboratories.215
Figure 14 summarizes the recommendations from Section 6.
F I G U R E  14   Investigation of sudden death. Colors correspond to the Class of Recommendation in Table 1. AED, automated external 
defibrillator; CIED, cardiovascular implantable electronic device; ECG, electrocardiogram; SCD, sudden cardiac death
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7  | INVESTIGATION OF SUDDEN C ARDIAC 
ARREST SURVIVORS
7.1 | Investigation of sudden cardiac arrest 
survivors: history— personal and family
When an individual has been resuscitated after SCA, the clinician 
must try to define the likely underlying cause, similar to that dis-
cussed in Section 6.1 focused on SCD. This should include informa-
tion on age, sex, past medical history, recent symptoms, activity 
or emotional status at the time of SCA (eg, sleeping, exercising, or 
emotion), time of onset (eg, morning or night), and environment (eg, 
public or private location), exposure to medicinal or recreational 
drugs (particularly those that block potassium or sodium channels) 
or alcohol, and a detailed family history of three generations at least.
To focus the history taking, one must consider the differential 
diagnosis of SCA, which is similar to that discussed in Section 6.1. If 
the SCA was observed, a description of the event by the observer 
can add useful information. All records of the primary event, includ-
ing initial rhythm recordings and details of the resuscitation, should 
be collected in addition to any prior ECGs and imaging studies. A 
family history of heart disease, syncope, or sudden death may point 
to a genetic cause. A study by Waddell- Smith et al77 showed that 
while inpatient cardiology teams identified a familial condition in 
only about 8% of cases, nurses trained in taking a family history de-
tected a familial condition in 32% of cases. Thus, although most pa-
tients with SCA will be in a nonspecialty environment at first, ideally 
specially trained members of the cardiology and genetic counselor 
team with experience in genetic heart disorders should be utilized 
to elicit relevant details of the family history. Practical educational 
assistance can be found at https://www.prima rycar egene tics.org.
Recommendations for investigation of SCA survivors: personal and 
family history
COR LOE Recommendations References
1 B- NR 1. In the investigation of an SCA 
survivor, detailed personal 
and three- generation family 
history should be taken with the 
assistance of a multidisciplinary 
team, including witness accounts.
77
1 B- NR 2. All possible details surrounding 
an SCA event should be sought, 
including patient's recollection, 




Observational studies have demonstrated that the cause of SCA 
can be determined in a substantial proportion of patients. Historical 
features, especially age, coronary risk factors, symptoms, activity at 
the time of SCA, exposure to drugs, and family history frequently 
provide important clues to the diagnosis and point the way to fur-
ther investigation.
Recommendation- specific supportive text
1. In a study of 37 patients with history of SCD, cardiomyopathy, 
or ventricular tachycardia, a family history obtained by specially 
trained personnel was far more likely to elicit a history of inherited 
cardiac disease than one obtained by an inpatient cardiac team.77
2. A detailed history is a crucial component of diagnosing the cause 
of SCA. Studies utilizing a comprehensive, systematic approach 
including history, physical examination, ECGs (eg, 12- lead ECG, 
treadmill, 24- hour Holter, signal- averaged ECG, if needed), car-
diac imaging (eg, coronary angiography, echocardiogram, CMR, 
CT), provocative testing, electrophysiological study, cardiac bi-
opsy, and genetic testing have shown that a diagnosis can be es-
tablished in a substantial proportion of survivors of SCA.216– 219
7.2 | Investigation of sudden cardiac arrest 
survivors: examination
The next step in cardiac evaluation of SCA survivors is physical exami-
nation. The main purpose is to identify signs of syndromic and non-
syndromic diseases that can be associated with SCA. For example, 
obesity and/or the presence of xanthomata may indicate an increased 
likelihood of premature coronary atherosclerosis.221,222 Syndromic 
features that may be relevant to genetic disorders include woolly 
hair and palmoplantar keratoderma (arrhythmogenic right ventricu-
lar cardiomyopathy),140 joint contractures (Emery- Dreifuss muscular 
dystrophy),223 muscle weakness and atrophy (lamin A/C and desmin 
cardiomyopathies, Triadin knockout syndrome),224 micrognathia, syn-
dactyly, clinodactyly (Andersen- Tawil and Timothy syndromes),224 
chest and limb deformities, and tall stature (Marfan syndrome).225,226
Fever, hypothermia, dehydration, and signs of drug abuse may 
be detected on physical examination, although these signs may 
be confounded by neurological impairment after cardiac arrest. 
These factors can trigger life- threatening arrhythmia in genetic 
heart disease. For example, fever has been associated with malig-
nant arrhythmias in 6% of patients with cardiac arrest and Brugada 
syndrome.136
Cardiac murmurs can raise the suspicion of left ventricular out-
flow tract obstruction, mitral mid- systolic click (valve prolapse) with 
or without regurgitation, and Ebstein anomaly. Signs of pulmonary 
edema and hepatosplenomegaly can be detected in patients with se-
vere systolic myocardial dysfunction. Importantly, examination find-
ings may be affected by the SCA event and evolve during a hospital 
stay, requiring repeated physical examination to determine whether 
findings are related to the cause of SCA or the effect of SCA.
Recommendation for investigation of SCA survivors: examination
COR LOE Recommendation References
1 B- NR 1. Detailed physical examination is 
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Synopsis
There are no data describing the usefulness of physical exam-
ination in resuscitated SCD. However, it is a first basic step in the 
diagnostic process that will focus subsequent complementary 
investigations.
Recommendation- specific supportive text
1. Protocols for clinics investigating SCA survivors support the 
use of physical examination as the first step of clinical 
overview.10,216,227
7.3 | Investigation of sudden cardiac arrest 
survivors: baseline investigations
In most emergency settings, a patient resuscitated from cardiac ar-
rest in whom myocardial infarction is suspected will have undergone 
a coronary reperfusion strategy to treat acute occlusion. It is critical 
to obtain blood tests (cardiac enzymes, inflammatory markers, glu-
cose, serum electrolytes, and white blood cell count) and pertinent 
toxicological analysis at presentation. The latter may include testing 
for drugs of abuse such as ethanol, opiates, and stimulants, as well 
as levels of prescribed medication that may prolong QT interval/
QRS duration or cause respiratory depression.228 While assisting in 
the acute management of a resuscitated patient, these results will 
also help to differentiate acute myocardial injury as a cause of car-
diac arrest (eg, ischemia without clear evidence of coronary occlu-
sion or myocarditis) and pick up other reversible causes such as drug 
overdose, electrolyte imbalance, or endocrine and metabolic disor-
ders. Retention and storage of suitable blood samples on patient ar-
rival in the emergency department will allow subsequent diagnostic 
evaluation including DNA extraction and analysis in a patient who 
dies prior to diagnosis or for later clinical and family review. In some 
cases, this may be the only opportunity to obtain genetic material 
for analysis.
In an OHCA, the use of AEDs is ever more widespread and in-
creases survival.229 Sensitivity for the diagnosis of cardiac rhythm at 
the time of arrest is about 99%.230 Therefore, routine inspection of 
data from AED recordings may improve the quality of diagnosis (see 
Section 6.2). The underlying rhythm of cardiac arrest may provide 
information on the arrhythmogenic mechanism, assist in diagnosis, 
and eventually indicate any misdiagnosis of rhythm.231 Any ECG 
tracings from emergency services, as well as recordings from inter-
rogation of CIEDs or wearables can also contribute to diagnosis.163
The 12- lead ECG in sinus rhythm or during arrhythmia recur-
rence is fundamental to the diagnostic investigation and should be 
repeated daily during recovery.216 It may support diagnoses of pri-
mary electrical disorders, pre- excitation, and heart muscle diseases. 
However, abnormalities of cardiac conduction and repolarization 
may result from myocardial injury during the cardiac arrest and 
patients undergoing post- arrest hypothermia protocols may have 
transient ECG changes including QT prolongation and J point ele-
vation that should be interpreted with caution. Information about 
electrolyte levels, drug prescription, and body temperature should 
be added to the ECG to prevent misinterpretation of such ECG ab-
normalities. A high precordial lead ECG is an inexpensive tool to in-
crease detection of Brugada syndrome pattern.184,232– 235
In addition to standard ECG, a signal- averaged ECG may demon-
strate late potentials. Two or more abnormalities in the absence of a 
prolonged QRS duration (≥110 ms) on the standard ECG is a minor di-
agnostic criterion for arrhythmogenic cardiomyopathy and suggests 
ventricular depolarization abnormality.4
Continuous heart rhythm monitoring is recommended during 
hospitalization due to the transient nature of some arrhythmias. 
Recording the onset (including pause- dependent or tachycardia- 
associated initiation) and late and short- coupled ventricular ectopics 
as triggers for torsade de pointes, polymorphic ventricular tachy-
cardia, or ventricular fibrillation will elucidate cardiac arrest mech-
anism and likely diagnosis.236 Evidence of dynamic ST elevation 
associated with chest pain may also indicate likelihood of coronary 
vasospasm.216
Echocardiography is the screening tool of choice for structural 
heart disease, although early myocardial dysfunction may be present 
after cardiac arrest and, if present early, the test should be repeated 
later during the patient's convalescence. CMR allows detection of 
inflammatory diseases, such as myocarditis and sarcoidosis, through 
recognition of subepicardial edema. Identification of an inflamma-
tory etiology is important, as it may be self- limiting or treatable. If 
sarcoidosis is suspected, then positron emission tomography– CT 
scanning may be indicated.237 The presence of subendocardial 
edema would suggest ischemic injury.238 Late gadolinium enhance-
ment indicates chronic fibrosis, permitting detection of a cardiomyo-
pathic etiology, and can also contribute to the diagnosis of mitral 
valve prolapse associated with a risk of SCD.239,240 Coronary imag-
ing (at any age) will be important to exclude coronary artery disease 
not investigated at presentation as an emergency and ensure that 
an anomalous coronary circulation or coronary dissection is not 
missed.241 This may be by cardiac catheterization or by CT coronary 
angiography.242 Coronary angiography will only be required in select 
pediatric and young survivors.
Patients in whom the cause of their SCA remains undiagnosed 
may require periodic re- evaluation of the above investigations, as 
features may develop later that point to a cause of their SCA (similar 
to Section 6.5, Recommendation 1).
Recommendations for investigation of SCA survivors: baseline 
investigations
COR LOE Recommendations References
1 B- NR 1. Blood samples for electrolytes, 
toxicology, and EDTA blood stored 
for future genetic testing are 
recommended for all SCA survivors 
on admission to hospital.
228
1 B- NR 2. Retrieval of recordings from 
CIEDs and wearable monitors is 
recommended for all SCA survivors.
243– 245
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Recommendations for investigation of SCA survivors: baseline 
investigations
COR LOE Recommendations References
2b C- LD 3. Retrieval of recordings from AEDs 
and ambulance services may be 
useful for all SCA survivors.
158,170
1 B- NR 4. Recording of 12- lead ECGs during 
sinus rhythm and, if possible, during 




1 C- LD 5. A high precordial lead ECG is 
recommended in all undiagnosed 
SCA survivors to increase detection 
of a type 1 Brugada ECG pattern.
189,232– 235
1 C- LD 6. Continuous ECG monitoring is 
recommended for all SCA survivors 
during the initial hospital stay.
85,216,246
2b C- LD 7. A signal- averaged ECG may be 
useful in SCA survivors to aid in 
the diagnosis of arrhythmogenic 
cardiomyopathy.
247
1 B- NR 8. Echocardiography is recommended 
for evaluation of cardiac structure 
and function in all SCA survivors.
85,216
1 B- NR 9. CMR with late gadolinium 
enhancement is recommended 
for evaluation of acute or chronic 
myocardial disease in SCA survivors 
without a clear underlying cause.
238,248
2a B- NR 10. CMR can be useful for evaluation 
of acute or chronic myocardial 
disease in SCA survivors, when 
the etiology is primary electrical or 
there is evidence for acute cardiac 
ischemia.
238,248
1 B- NR 11. Coronary imaging is recommended 
in all adult SCA survivors, to exclude 
coronary artery disease, dissection, 
or anomalies not considered fully 




Systematic clinical testing is paramount in SCA survivors. This 
includes blood testing, toxicology, ECG, signal- averaged ECG, high 
precordial lead ECG, continuous ECG monitoring, echocardiography, 
and coronary imaging. If the diagnosis remains elusive and cardiac 
arrest is deemed unexplained, then CMR is important to identify 
subtle forms of cardiomyopathy or acquired structural disease.
Recommendation- specific supportive text
1. The usefulness of blood testing and toxicology is by consensus, 
and a diagnostic role is unquestionable.2,10,228 Viral studies may 
be useful, but no systematic evidence is available as yet.249 A 
potential role for biomarkers specific for one of the arrhythmia 
syndromes is anticipated.250,251
2. Results of a forensic study indicate the value of postmortem 
CIED interrogation to define the cause and timing of death more 
accurately and to detect potential CIED- related safety issues. 
CIED interrogation in unexplained deaths clarified the manner of 
death in 60.8% of the cases including cardiac and nonarrhythmic 
death and device concerns.163
3. Sensitivity for the diagnosis of cardiac rhythm via AED at the time 
of arrest is about 99%.230 However, the AED seldom catches the 
initial rhythm of cardiac arrest and therefore may not contribute 
to the etiology of SCA.
4. Primary electrical disorders and specific cardiomyopathies may be 
detected by conventional ECG.2,10,216,252 ECG findings in the imme-
diate aftermath of a cardiac arrest, other than ST- segment eleva-
tion indicative of an acute coronary syndrome, may, however, have 
poor diagnostic accuracy.253,254 These could be caused by abnormal 
repolarization following electrical cardioversion,255 metabolic and 
electrolyte abnormalities, or even subarachnoid hemorrhage.256 
Therapeutic hypothermia may lead to misleading ECG changes 
such as prolongation in PR, QRS and QT intervals, and J point eleva-
tion.257,258 Interpretation of ECGs obtained immediately after resus-
citation/defibrillation should be performed with great caution.
5. Although there are no data describing directly the value of high 
precordial lead ECGs in SCD survivors, there is ample evidence of 
an increased yield of the type 1 Brugada ECG pattern.189
6. Cardiac monitoring during short- term follow- up demonstrates an 
arrhythmogenic mechanism of SCD in some registries.216,236,246
7. Signal- averaged ECG is part of the Task Force Criteria for arrhythmo-
genic right ventricular cardiomyopathy.4 Signal- averaged ECG has 
been proposed as useful in other conditions (ie, Brugada syndrome), 
although systematic evaluation has not been performed.
8. Echocardiography is a valuable screening tool for detection of 
arrhythmogenic cardiomyopathy and other structural abnormali-
ties useful in elucidating the cause of SCA.85 Patients with func-
tional abnormalities on initial echocardiogram should have this 
test repeated after recovery, to allow for the effects of the SCA 
itself and drugs used around the time of the arrest to wear off.
9.      and 10. The utility of CMR has been evaluated in a series of stud-
ies involving survivors of unexplained arrest and has repeatedly 
been shown to provide significant incremental diagnostic value. A 
study of 137 individuals with unexplained aborted cardiac arrest 
found that CMR provided a diagnosis or identified an arrhythmic 
substrate in 76% of individuals, including an infarct pattern sugges-
tive of occult myocardial infarction in 44%. Notably, the presence 
of late gadolinium enhancement, reflective of myocardial fibro-
sis, was associated with a 6.7 hazard ratio (P < .001) of recurrent 
arrhythmic events on multivariate analysis.248 The presence of 
subendocardial edema would suggest ischemic injury even when 
initial coronary imaging excludes significant obstruction. Coronary 
vasospasm and dissection might be misdiagnosed, and coronary 
re- evaluation may then be reconsidered.238 The frequency of 
occult infarcts is not insignificant,248 although the risk of SCD in 
patients with myocardial infarction and nonobstructive coronary 
arteries is low.259 For Recommendation 10, primary electrical dis-
ease is not referring to an established diagnosis of long QT syn-
drome or CPVT, where MRI is unlikely to be of use.
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11. Coronary artery disease is the leading cause of SCD in adults and 
might be treatable. Furthermore, coronary dissection and anoma-
lies may also be relevant in this age group as well as in younger 
patients.
7.4 | Investigation of sudden cardiac arrest 
survivors: provocative testing
Once a cardiac arrest survivor has undergone initial thorough base-
line evaluation, most overt acquired or genetic etiologies will have 
been diagnosed. However, concealed disorders may be uncovered 
by provocative maneuvers such as lying to standing ECGs, exercise 
ECG testing, epinephrine challenge, sodium channel blocker chal-
lenge, or ergonovine and acetylcholine testing. Some may even be 
employed in a resuscitated cardiac arrest survivor who is unlikely to 
survive due to neurological injury.
Exercise testing may uncover ventricular arrhythmia relevant 
to the cause of cardiac arrest. For example, evidence of monomor-
phic ventricular tachycardia arising from the right ventricle is part 
of Task Force Criteria for diagnosis of arrhythmogenic right ven-
tricular cardiomyopathy (arrhythmogenic cardiomyopathy).260– 262 
Exercise may also uncover concealed epsilon waves or even a type 
1 Brugada ECG pattern.263,264 The generation of bidirectional 
ventricular ectopy or tachycardia and/or polymorphic ventricular 
tachycardia in the absence of ischemia, structural disease, or di-
goxin toxicity is typical of CPVT265 and has been evaluated in the 
Cardiac Arrest Survivors with Preserved Ejection Fraction Registry 
(CASPER) protocol.216 Abnormal dynamics of repolarization in re-
sponse to challenges may also inform the likelihood of underlying 
long QT syndrome. To this end, maximum QT prolongation (QT 
stretch) and T- wave morphology changes during lying to standing 
and then return to baseline heart rate (QT stunning) may be useful 
markers, although they are less specific in children.266– 268 These 
discriminate well in genotyped families and may add to diagnos-
tic utility, but evaluation in unexplained cardiac arrest survivors 
has not been undertaken.269 The recovery phase of exercise may 
also reveal readily measurable QT prolongation and T- wave abnor-
malities and has been validated in families with long QT syndrome 
for prediction of genotype270,271 and in cardiac arrest survivors216 
such that a QTc >480 ms at 4 min of recovery forms part of the 
long QT syndrome risk score.272
Epinephrine challenge with ECG monitoring has been advo-
cated as an alternative to exercise testing for the diagnosis of long 
QT syndrome and CPVT, particularly where the patient is unable 
to exercise. In long QT syndrome, QT prolongation and secondary 
T- wave changes have been able to discriminate LQT1 and LQT2 
patients from unaffected family members even though they have 
normal baseline QTc intervals.273,274 The test has been assessed in 
unexplained cardiac arrest survivors and has suggested a low spec-
ificity for long QT syndrome.275 The finding would be unlikely to 
provide a secure diagnosis in isolation and was proposed as use-
ful in association with exercise testing and genetic testing. Indeed, 
in normal subjects, pharmacological sympathetic stimulation does 
produce significant prolongation of QTc.276 Epinephrine testing has 
also shown some diagnostic utility for CPVT in cardiac arrest survi-
vors by inducing ventricular ectopic activity, bidirectional couplets, 
and ventricular tachycardia.275 However, there is uncertainty as to 
the ideal cutoff for epinephrine- induced arrhythmia, and the diag-
nostic sensitivity compared to exercise testing in CPVT families is 
low.277 Isoproterenol challenge for the diagnosis of arrhythmogenic 
right ventricular cardiomyopathy has also been advocated but has 
not been tested by other groups or in the unexplained cardiac arrest 
survivor without overt phenotype.278
Sodium channel blocker challenge (ajmaline, procainamide, 
flecainide, and pilsicainide) has been used extensively for investi-
gating the possibility of Brugada syndrome in cardiac arrest survi-
vors, although these are mainly reported in series of patients with 
a strong suspicion of Brugada syndrome279– 281 rather than in unex-
plained cardiac arrest survivors.282 The use of leads V1 and V2 in 
the second and third intercostal space or high right precordial ECG 
leads during provocation increases the diagnostic yield.233,283 In the 
CASPER registry, there was a yield from procainamide challenge,284 
although this may underestimate the true burden, as different so-
dium channel blockers have different potencies for inducing the 
type 1 Brugada ECG pattern. For example, ajmaline is associated 
with an odds ratio of 8 for inducing the type 1 Brugada ECG pattern 
compared with procainamide285 and a 4% yield in a small group of 
“healthy” controls.286 Furthermore, while recent consensus guide-
lines would give a definite diagnosis to a cardiac arrest survivor with 
a type 2 or 3 pattern converting to a type 1, the implication of a 
drug- induced type 1 pattern without a baseline type 2 or 3 is not 
addressed.152 Yet cardiac arrest survivors from CASPER without a 
type 2 or 3 pattern had positive procainamide challenges.284 Other 
tests such as the full stomach test have been proposed but have not 
been taken up in general.287
Different approaches for provocation of an underlying repolar-
ization abnormality have been employed including drug challenge 
with quinidine and sotalol and mental stress tests.288– 291 These may 
offer utility in the future but have not been tested in the cardiac 
arrest survivor.
Coronary vasospasm, while a recognized cause of cardiac arrest, 
may not be picked up clinically at presentation.292 Ergonovine or 
acetylcholine challenge has been proposed as a Class 1 indication 
by recent guidelines293 and was employed selectively in the CASPER 
experience.216 Hyperventilation has also been used as a diagnostic 
test.294 Recent experience from the Paris Sudden Death Expertise 
Center investigators suggests that pharmacological challenge is 
useful for diagnosis and could be better employed.295 Nonetheless, 
there are few centers with extensive experience in the use of the 
test, and there is a possibility of false- positive findings in the cardiac 
arrest survivor population.
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Adenosine challenge has been used to unmask pre- excitation 
that may otherwise be missed.296,297 In the absence of other 
causes, it will indicate the need for electrophysiological study to 
evaluate the risk of the accessory pathway (rapidity of antegrade 
conduction) followed by ablation therapy. However, electrophys-
iological study is not routinely included in the workup of unex-
plained cardiac arrest.8 Indeed, previous consensus guidelines 
proposed a Class 3 indication when assessing a suspected primary 
electrical disorder.8 It does not add additional diagnostic or prog-
nostic value unless there is evidence to indicate otherwise. For 
example, pre- excited atrial fibrillation, bundle branch re- entrant 
ventricular tachycardia, and rapid supraventricular tachycardias 
that degenerate into ventricular fibrillation have all previously 
been described as culprits requiring an invasive approach to diag-
nosis and curative ablation therapy.298,299 Electroanatomic volt-
age mapping of the right ventricle is a discretionary tool that may 
be considered to detect evidence of subclinical arrhythmogenic 
right ventricular cardiomyopathy.300 More recently, extensive en-
docardial and epicardial mapping of unexplained cardiac arrest 
cases has been employed to identify cases with either Purkinje 
triggers and/or subtle depolarization abnormalities that may be 
suitable for ablation therapy.301
Recommendations for investigation of SCA survivors: provocative 
testing
COR LOE Recommendations References
1 B- NR 1. Exercise testing is recommended 
in all undiagnosed SCA survivors 
to induce arrhythmias that 
may support the diagnoses of 
arrhythmogenic cardiomyopathy 
and CPVT and to evaluate 
dynamic depolarization or 
repolarization features that may 
support the diagnoses of Brugada 
syndrome, arrhythmogenic 




2a B- NR 2. Lying to standing ECGs can be 
useful in SCA survivors for the 
diagnosis of long QT syndrome, but 
must be interpreted with caution in 
children.
266– 270
2b B- NR 3. Epinephrine challenge may be 
considered for the diagnosis of long 
QT syndrome and CPVT, in those 
unable to exercise.
273– 275,277,304
1 B- NR 4. Sodium channel blocker challenge 
with standard and high precordial 
ECG leads is recommended for the 
diagnosis of Brugada syndrome in 
undiagnosed SCA survivors with 
suggestive clinical characteristics, 




Recommendations for investigation of SCA survivors: provocative 
testing
COR LOE Recommendations References
2a B- NR 5. Sodium channel blocker challenge 
with standard and high precordial 
ECG leads can be useful for the 
diagnosis of Brugada syndrome 
in SCA survivors where no other 
disorder has been identified.
233,279– 282
2b B- NR 6. Ergonovine, acetylcholine, or 
hyperventilation testing when 
performed in experienced centers 
may be considered for the diagnosis 
of coronary vasospasm as the cause 
of SCA in a survivor where no other 
disorder has been identified.
216,294,295
2b C- LD 7. Adenosine challenge may be useful 
for the unmasking of ventricular 
pre- excitation and therefore the 
diagnosis of rapidly conducted 
atrial arrhythmia as the likely cause 
of SCA in a survivor where no other 
disorder has been identified.
297
2a C- LD 8. An electrophysiological study can 
be considered if bundle branch 
re- entrant ventricular tachycardia, 
pre- excited atrial fibrillation, or 
supraventricular tachycardia are 
suspected in an SCA survivor.
298,299
2b C- LD 9. Electroanatomic right ventricular 
voltage mapping may be considered 
for detection of subclinical 
arrhythmogenic cardiomyopathy 
in an SCA survivor where no other 
disorder has been identified.
300
2b C- LD 10. An electrophysiological study may 
be considered in an SCA survivor 
where no other disorder has been 




Concealed Brugada syndrome, long QT syndrome, CPVT, ar-
rhythmogenic cardiomyopathy, pre- excitation, and coronary vaso-
spasm may be uncovered by provocative maneuvers in the cardiac 
arrest survivor whose cause of cardiac arrest remains unknown 
after baseline clinical, ECG, and imaging investigations. Exercise 
ECG testing and sodium channel blocker challenge appear to offer 
most potential utility, whereas lying to standing ECGs; epinephrine, 
isoproterenol, and adenosine challenge; and hyperventilation, er-
gonovine, and acetylcholine testing may be considered in specific 
patients. Electrophysiological study and electroanatomic mapping 
may be useful to provide patient- specific insights into the mecha-
nism of cardiac arrest and offer therapeutic options but should be 
avoided in the routine investigation of channelopathy. However, 
data in general are limited to case reports or case series, some with 
validation cohorts, and there are no randomized studies.
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F I G U R E  1 5   Investigation of 
sudden cardiac arrest (SCA) survivors: 
genetic evaluation. Colors correspond 
to the Class of Recommendation in 
Table 1
7. Adenosine challenge has not been tested systematically in car-
diac arrest survivors, but there are limited data suggesting that 
it will uncover concealed pre- excitation that may cause car-
diac arrest in the setting of rapidly conducted pre- excited atrial 
tachyarrhythmias.296,297
8. There are limited case series describing the use of electrophysiolog-
ical study in diagnosis and treatment of pre- excited atrial arrhyth-
mias and bundle branch re- entrant ventricular tachycardia.298,299
9. Studies of endocardial mapping report a higher sensitivity for 
detection of arrhythmogenic cardiomyopathy, but this has not 
been explored in SCA survivors.300 Sensitivity and specificity 
are unknown, particularly in patients where no other tests are 
abnormal.
10. Extensive endocardial and epicardial mapping of unexplained car-
diac arrest cases has been employed to identify cases with either 
Purkinje triggers and/or subtle depolarization abnormalities that 
may be suitable for ablation therapy.301
7.5 | Investigation of sudden cardiac arrest 
survivors: genetic evaluation
Although most SCA survivors will have an indication for an implant-
able defibrillator for secondary prevention of a cardiac arrest,6 
genetic evaluation may influence final diagnosis, treatment recom-
mendations, and family screening (Figure 15). In some cases, genetic 
evaluation may enable therapy specific to the disease mechanism. 
Recent technological advances in genetic evaluations, establishment 
of reference databases of genetic variants, systematic annotation of 
causal genes,305 and standardization of variant interpretation306 have 
enabled efficient and comprehensive genetic assessment. However, 
the pace of genetic discovery and variant interpretation is evolving 
rapidly, creating a complex landscape surrounding genetic evaluation 
of SCA survivors.
The decision to pursue genetic evaluation is an individual-
ized one in which the patient, with proper (clinical and genetic) 
Recommendation- specific supportive text
1. Exercise testing is a versatile, straightforward, and readily 
available test that may yield diagnoses due to the arrhyth-
mic challenge or effects on depolarization and repolarization. 
As such, it should be a standard part of the investigative 
armamentarium.216,220,263– 265,270– 272,302,303
2. Lying to standing ECGs may offer some insights into the likelihood 
of long QT syndrome, but in isolation a positive result may not 
fulfill diagnostic criteria and therefore may only complement the 
evaluation.266– 270
3. Similarly, epinephrine challenge has low specificity for long QT 
syndrome and may be insensitive for CPVT. In isolation, a positive 
result may not fulfill diagnostic criteria and therefore may only 
complement the evaluation.273– 275,277,304 There are risks to this 
test, both in inducing ventricular arrhythmia and in false diagnosis.
4. Sodium channel blocker testing has a clear role to play in evaluating 
the cardiac arrest survivor, although the implication of a positive re-
sult in patients with or without a high prior likelihood of Brugada syn-
drome is unclear, eg, male vs. female, cardiac arrest during sleep vs. 
exercise, type 2 or 3 ECG pattern vs. no Brugada pattern at baseline. 
This reflects the lack of a gold standard for the diagnosis of Brugada 
syndrome, and therefore the utility of sodium channel blocker chal-
lenge in patients without a clear prior likelihood of Brugada syn-
drome is less certain and merits a lower utility in the evaluation cas
cade.233,273– 275,277,286 Furthermore, sodium channel blocking agents 
differ in their sensitivity and specificity for inducing ECG changes and 
availability varies worldwide (see Section 7.4 text).285
5. See 4.233,279– 282
6. The utility of ergonovine or acetylcholine challenge or hyperven-
tilation testing in all cardiac arrest survivors is unclear, as there 
are no studies of systematic testing in all cardiac arrest survivors. 
In particular, the specificity of the test is unknown, especially in 
the cardiac arrest survivor population. It can, however, lead to di-
agnoses when employed in a protocol and therefore should be 
considered as part of the armamentarium until more evidence is 
available.216,293– 295
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counseling, must weigh the benefits, limitations, and personal and 
familial implications. The genetic basis of SCA and most individual 
conditions that predispose to SCA remain incompletely understood. 
As such, caution is advised when interpreting negative genetic test 
results or when examining genes with low likelihood of causing 
SCA. Prior clinical practice guidelines have specifically addressed 
the diagnostic considerations regarding specific genetic cardiovas-
cular conditions.4,10,307 The ClinGen represents a systematic effort 
to enumerate causal genes and variation related to human disease, 
including SCA- related conditions.305 Previous reports have been de-
veloped for Brugada syndrome,195 long QT syndrome,196 and hyper-
trophic cardiomyopathy.202
The yield of genetic testing varies substantially by condi-
tion.188 Variant interpretation may differ by laboratory215 de-
spite recent efforts to standardize variant interpretation.306 
Given the rapid changes in available technology to evaluate 
the genome, complexities in variant interpretation, and nu-
ances in the ethical and legal framework surrounding genetic 
testing in some settings,66,106,215,308– 310 it is recommended 
that SCA survivors undergoing genetic assessment have eval-
uations performed at centers with multidisciplinary experience 
in counseling, variant interpretation, and management of ge-
netic heart disease (see Section 3). For SCA survivors who have 
undergone genetic testing, an offer of periodic re- evaluation 
of the genetic test results is advocated (similar to Section 6.4, 
Recommendation 4).
Recommendations for genetic evaluation of SCA survivors
COR LOE Recommendations References
1 B- NR 1. Genetic evaluation of SCA 
survivors is recommended 
for those with a diagnosed or 
suspected genetic cardiac disease 
phenotype when the results 
are likely to influence diagnosis, 
management, or family screening.
84,311– 322
1 B- NR 2. When genetic evaluation is 
performed in an SCA survivor with 
a suspected or diagnosed genetic 
cardiac disease phenotype, it is 
recommended that evaluations 
include only genes where there is 
robust gene– disease association.
84,308
2b B- NR 3. When genetic evaluation is 
performed in an SCA survivor 
with a suspected or diagnosed 
genetic cardiac disease phenotype, 
assessment of genes or genomic 
regions that are not known to be 
causally related may be considered 
in select circumstances.
84
2b B- NR 4. Genetic evaluation of SCA 
survivors without a distinct genetic 
cardiac disease phenotype may be 
considered in select circumstances.
82,84,209,
246,323– 330
Recommendations for genetic evaluation of SCA survivors
COR LOE Recommendations References
3: No 
Benefit
C- EO 5. Genetic testing in SCA survivors 
with a well- established nongenetic 
cause of SCA is not recommended.
Synopsis
SCA can be caused by diverse etiologies, some of which may be pre-
dominantly or partially influenced by genetic predisposition. Whereas 
a thorough clinical evaluation leads to a diagnosis of the cause of SCA 
for most individuals, the cause of SCA may remain uncertain in oth-
ers.216 In some cases, genetic evaluation of SCA survivors can confirm 
a molecular etiology that predisposed to the SCA event, support the 
diagnosis of a specific phenotype, influence management, and facili-
tate screening in family members at risk via cascade genetic testing.
Recommendation- specific supportive text
1. Genetic testing, after appropriate genetic counseling and in-
formed consent, may facilitate identification of a molecular 
cause of SCA by identifying pathogenic variants in genes as-
sociated with specific phenotypes and fulfilling formal disease- 
based diagnostic criteria.4,10 Examples of scenarios in which 
discovery of a genetic cause of SCA may influence management 
recommendations include administration of beta blockade for 
patients with long QT syndrome,311 sodium channel inhibition 
in long QT syndrome type 3,312– 314 flecainide administration 
for patients with CPVT,315,331 or exercise restriction recom-
mendations in patients with arrhythmogenic cardiomyopa-
thy.316,317 Genetic evaluation may also influence family screening 
by facilitating cascade genetic testing and clinical surveillance 
in relatives at greatest risk for disease.
2. and 3. Genetic tests have variable yield and may result in 
discovery of variants of uncertain clinical significance, which 
can be frequent and challenging to interpret. Using genetic 
tests that comprise well- established genes related to a suspected 
or diagnosed genetic phenotype is most likely to result in dis-
covery of disease- causing variants in an individual or family, 
while minimizing the probability of discovering a variant of 
uncertain clinical significance. In contrast, genetic tests with 
more comprehensive genomic coverage may lead to moderately 
increased diagnostic yield but at the expense of increased rates 
of discovery of variants of uncertain clinical significance.84,308 
Nevertheless, given a rapidly evolving understanding of the 
molecular causes of specific phenotypes and increased yield 
of broader genetic assessment,82,84,246,323,324 tests that include 
broader coverage may be considered in select circumstances, 
such as when a heritable phenotype is being mapped within 
a family or assessment for de novo variation is sought through 
sequencing of multiple family members. The latter examples 
would only be pertinent when it becomes apparent that a 
familial trait is likely or there has been exome sequencing in 
a trio of confirmed parents and the index case.
4. Genetic evaluation appears to be highest for individuals with 
a phenotype consistent with a genetic cause84,323,324 and is 
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lower among SCA survivors without a clearly identifiable genetic 
phenotype.82,84,246,323– 326 Nevertheless, individuals with an idi-
opathic cause of SCA may eventually develop a diagnosis of 
a genetic etiology during long- term follow- up.327 Genetic testing 
can identify variants during the concealed phase of a genetic 
disease such as arrhythmogenic cardiomyopathy,328 or in indi-
viduals with conditions otherwise regarded as nongenetic such 
as in drug- induced long QT syndrome.329 As such, a low but 
non- negligible yield for genetic testing appears to be present 
among individuals with idiopathic SCA.
5.   In individuals with a well- established nongenetic cause of SCA, the rou-
tine use of genetic evaluation is not recommended owing to the potential 
for discovery of variants of uncertain significance and misdiagnosis.
Figure 16 summarizes the recommendations from Section 7.
8  | INVESTIGATION OF THE FAMILY
8.1 | Background
The sudden death of a young, apparently healthy individual raises 
many questions for family members. Apart from mourning and 
the question “could we have done something to avoid this,” a very 
relevant question is whether family members could be affected 
as well. Roles for health care providers include providing psycho-
logical support for the family, identifying a cause for the sudden 
death, and understanding the implications for family members 
(see Sections 4 and 5). For this chapter, it is especially relevant 
that families need support to organize clinical and genetic testing 
for family members and sometimes postmortem genetic testing 
of the deceased.2,100,332
F I G U R E  1 6   Investigation of sudden cardiac arrest survivors. Colors correspond to the Class of Recommendation in Table 1. AED, 
automated external defibrillator; AF, atrial fibrillation; BBR- VT, bundle branch re- entry ventricular tachycardia; CIED, cardiovascular 
implantable electronic device; CMR, cardiac magnetic resonance imaging; CPVT, catecholaminergic polymorphic ventricular tachycardia; 
ECG, electrocardiogram; EP, electrophysiological; LQTS, long QT syndrome; SCA, sudden cardiac arrest; SVT, supraventricular tachycardia
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Currently, many cases and even familial forms of unexplained 
cardiac disease remain insufficiently investigated.333 When clinical 
symptoms indicate that a cardiomyopathy or arrhythmia may have con-
tributed to the death, further steps are needed to specify the diagnosis. 
If blood or tissue of the deceased is available, DNA testing can be done 
for a range of arrhythmia syndromes and cardiomyopathies, nowadays 
often using gene panels. Without a specific diagnosis in the deceased, 
clinical investigation of the first- degree relatives (parents, siblings, and 
children) can identify a person with similar symptoms or signs, although 
sometimes mild. This relative of the deceased can be the proband for 
DNA testing and thus provide the key to a diagnosis for the family.
Efforts are needed to increase the proportion of postmortem 
examinations (either forensic or medical autopsy) to clarify whether 
or not an underlying cause can be suspected or proven. The post-
mortem result should be communicated to the family as per local 
protocols. Without a postmortem diagnosis, efforts are needed to 
evaluate eventual clinical symptoms of the parents and other first- 
degree family members.80,81,143,144,334 This is outlined in Section 6. 
If DNA of the deceased person can be used for testing, or a relative 
who has similar symptoms can be tested, a monogenic form of car-
diomyopathy or arrhythmia may be recognized that may also be pres-
ent in family members. Typically, first- degree relatives are at 50% risk 
of carrying the same pathogenic mutation, since many of these con-
ditions follow an autosomal dominant pattern of inheritance.
Depending on whether or not autopsy has been performed, 
whether DNA is available, whether a relative is already diagnosed with 
a cardiogenetic condition, and whether symptoms were noticed during 
life, there are different situations possible: 1) sudden death, with clinical 
observations or DNA testing suggesting a specific diagnosis, and 2) sud-
den death, with no cause identified. The first situation will be discussed 
in Section 8.2, the second in Section 8.3 (Figure 17).
8.2 | Investigation of the family: cause identified— 
cascade testing, clinical and genetic investigations
In cascade testing, after the postmortem diagnosis in an index pa-
tient by a DNA test, an invitation can be sent to parents, brothers 
and sisters, and children.335 If any of the relatives is also diagnosed 
with the condition, a next circle of first- degree relatives is invited. If 
one of the first- degree relatives is not available (either deceased or 
not wanting to participate), second- degree relatives are invited, for 
instance, children of a deceased sibling. This systematic approach is 
very effective in autosomal dominant conditions, since first- degree 
relatives are at 50% a priori risk to carry the same pathogenic muta-
tion and second- degree relatives at 25% risk. For minors, the age 
at which treatment starts determines the age before which DNA 
testing is advised. This may differ between countries and conditions. 
DNA testing of minors is not advised if the result would have no 
consequences in childhood.
Presymptomatic DNA testing makes it possible to organize pre-
ventive measures, such as regular cardiological follow- up, use of 
medication (eg, beta blockers), lifestyle advice (eg, avoid intensive 
sports), implantable cardioverter- defibrillators, or reproductive 
planning.80,193,336– 342 Presymptomatic DNA testing also puts an end 
to uncertainty and fear for those family members who test nega-
tive.339 For them, follow- up investigations are no longer indicated.
In studies describing cascade screening, often the participation 
of relatives is limited.343– 348 This implies that many persons carry-
ing pathogenic variants remain undiagnosed and are at continued 
risk of sudden death. Increasingly, geneticists and other stakehold-
ers plea for an active approach to cascade testing for conditions 
where interventions are available.349– 351 Stakeholders agree on 
the importance of early diagnosis and informing the family.2,340,352 
Barriers to cascade screening include out- of- pocket expenses for 
the patient, limited resources for informing relatives, and privacy 
regulations.339,351,353,354 To benefit from predictive, personalized, 
and preventive medicine, the roles and responsibilities of stake-
holders in genetic testing as a preventive strategy need to be care-
fully aligned.
If clinical signs and symptoms suggest an inherited condition but 
no DNA test has been performed or no pathogenic variant has been 
identified, then history, examination, and clinical investigations of 
first- degree relatives are required to identify those at risk for SCD.
Recommendations for investigation of the family: cause identified— 
cascade testing, clinical and genetic investigations
COR LOE Recommendations References
1 C- LD 1. If a pathogenic or likely 
pathogenic variant that fits 
with the phenotype has been 
identified in an SCD proband, 
first- degree relatives should 
be offered DNA testing, with 




1 C- LD 2. SCA survivors should be 
encouraged to provide information 
to at- risk relatives, and health 
care providers should support and 
document this process.
350,357
1 C- LD 3. The effectiveness of treatment 
strategies and interventions 
in relatives with pathogenic or 
likely pathogenic variants of 
genes related to SCD should be 
investigated in clinical trials.
333,358
1 B- NR 4. In families affected by SCA, 
reproductive genetic counseling 
should be offered to discuss risks 




A postmortem diagnosis in a victim of SCD implies the pos-
sibility of avoiding sudden death in relatives. This requires an ac-
tive approach to inform parents, siblings, and children of the index 
case and offer clinical evaluation and potential genetic testing. A 
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multidisciplinary service should support all elements of recognizing 
an inherited cardiac disorder in a victim (pathologist), identifying 
pathogenic mutations (geneticist), clinical evaluation and surveil-
lance of carriers of the mutation (cardiologist), and supporting the 
patients and relatives (psychologist).
Recommendation- specific supportive text
1. Since undiagnosed cardiogenetic conditions can be life- 
threatening and since interventions are available to reduce 
the risk of sudden death, first- degree relatives who are at 
50% risk of carrying the pathogenic variant need to be in-
formed about the possibilities of clinical investigations and 
genetic testing.70,84,346,355,356 Second- degree relatives whose 
intervening first- degree relative refuses genetic testing (or is 
not available) should be offered testing due to a 25% risk.
2. Patients often can inform their relatives at risk, but medical pro-
fessionals increasingly feel ethically responsible to support this 
process.349,350,357 Supplying a letter for the patient to share with 
relatives is advised. Occasionally, directly contacting relatives 
may be possible in some jurisdictions. Studies have shown that 
there is substantial room for improvement of the uptake of family 
screening. Barriers include reluctance to consent to postmortem 
investigations, lack of information, and lack of funding for the ser-
vices. While the services needed should involve many disciplines 
(pathologist, cardiologist, geneticist), the systematic approaching 
of family members fits the specialty of clinical genetics well. To 
achieve a high uptake, a systematic approach is needed.
3. The identification of at- risk individuals leads to the question of 
whether all require active treatment. Prospective clinical studies 
are needed to answer this question. To balance pros and cons for 
survival and for quality of life on treatment, long- term follow- up of 
persons following the suggested surveillance and interventions is 
needed. Precision prevention advice should build on this evidence.
4. In families with genetically affected individuals (with or without 
clinical findings), detailed prenatal counseling and guidance re-
garding inheritance patterns, variant penetrance, and risk should 
be offered, and other options including preimplantation genetic 
diagnosis should be explored.336– 338
8.3 | Investigation of the family: cause not 
identified— clinical and genetic investigations
Sudden death in the young is always a tragedy for those lost and 
the remaining family. When the cause of sudden death is not iden-
tified, either because there was no postmortem examination or 
because the autopsy was negative, significant anxiety in the fam-
ily focuses on two major questions: why did the subject die sud-
denly and what risks apply to the remaining family members? An 
autopsy is typically requested, and in some jurisdictions mandated, 
but may not be completed because of cultural, family, or logistical 
limitations. When a postmortem examination establishes a cause 
of death, diagnosis transitions from SUD to death attributed to 
autopsy- related findings (see Section 8.2). When no underlying 
anatomic or toxicologic cause of death is identified with forensic 
autopsy, the description of the death goes from SUD to sudden 
arrhythmic death (syndrome)/SAD(S), since death is attributed to 
a presumed arrhythmia, or autopsy- negative SCD. In the case of 
nonspecific findings, follow- up of families should be similar to that 
with a negative autopsy.184,359
When sudden death is classified as SAD or autopsy- negative 
SCD (ie, SUD), the differential diagnosis includes a breadth of inher-
ited conditions that are predominantly ion channelopathies, with 
latent cardiomyopathy a consideration based on subtle autopsy 
findings. Causes include long QT syndrome, CPVT, short QT syn-
drome, Brugada syndrome, and arrhythmogenic cardiomyopathy. 
Careful review by a trained cardiac pathologist is recommended 
to ensure that assigned causes or absent causes are accurate (see 
Section 6.3).2
Recent studies have shown that a genetic evaluation of the de-
ceased subject's DNA associated with a clinical evaluation of first- 
degree relatives of the deceased subject retrospectively identified 
the cause of death in 20%– 40% of cases.70,80,81,143,144,189,334 In this 
situation, the identification of the cause of sudden death provides an 
explanation to the family and facilitates further cascade screening. 
In a second step, it will enable prevention measures in the family to 
limit the risk of a second death.
Recommendations for investigation of the family: cause not 
identified— clinical and genetic investigations
COR LOE Recommendations References
1 B- NR 1. Family screening should 
be advised in first- degree 
relatives of SUD subjects with 
a negative autopsy (or with no 
autopsy) when the decedent's 
age is <45 years (and in all 




1 B- NR 2. Family screening should 
include genetic testing and 
clinical evaluation when genetic 
testing of a proband with SUD 




2a B- NR 3. It is reasonable to take a 
medical history and perform 
physical examination, standard 
and high precordial lead ECG, 
echocardiography, and exercise 




2b C- LD 4. Depending on the results of 
other investigations (ECGs, 
echocardiography, and exercise 
testing), it may be reasonable 
to perform ambulatory cardiac 
rhythm monitoring and CMR 
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Recommendations for investigation of the family: cause not 
identified— clinical and genetic investigations
COR LOE Recommendations References
2a B- NR 5. It is reasonable to screen 
select postpubertal family 
members of SUD subjects 
with pharmacological testing 
including sodium channel 
blocker when baseline testing 
or proband findings increase 
suspicion of the target diagnosis.
143,189,205,
275,288,334
2b B- NR 6. It may be reasonable to screen 
first- degree relatives of SUD 
subjects with pharmacological 
testing including epinephrine 
challenge (if exercise testing is 





Screening of first- degree relatives of the SCD victim is informed 
by findings from the forensic investigation. Though the yield of ge-
netic testing is relatively low, results should be applied to all first- 
degree relatives in conjunction with clinical assessment. In the 
absence of genetic results, screening tests should include a medical 
history, standard and high precordial lead ECG, 24- hour ambulatory 
monitoring, echocardiography, and exercise test, with select use of 
pharmacological provocation and advanced imaging.
Recommendation- specific supportive text
1. Although autopsy is recommended, family screening after sudden 
death in young patients is effective even when an autopsy is not 
conducted. Broad screening of first- degree relatives with systematic 
testing is warranted.80,81,143,144,334 Combining molecular autopsy 
with clinical evaluation in surviving families increases diagnostic 
yield.70 The value of surveillance testing after negative evaluation is 
F I G U R E  17   Investigation of the family affected by sudden cardiac arrest and/or sudden unexplained death when cause is identified 
or not identified. Colors correspond to the Class of Recommendation in Table 1. CMR, cardiac magnetic resonance imaging; ECG, 
electrocardiogram; SCA, sudden cardiac arrest; SCD, sudden cardiac death; SUD, sudden unexplained death
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uncertain, though commonly undertaken until age 45 years (range: 
40– 50 years), with decreasing frequency with age.85 The context 
of SCD, the family history, and existing findings should inform the 
potential merits of ongoing surveillance, including frequency and 
duration. The age at which and from which onward surveillance 
is warranted depends on the (suspected) underlying condition.
2. When decedent genetic testing detects a pathogenic or likely patho-
genic variant, the result enables identification of all family members 
at risk of SCD.80,81,143,144,334 It is important to combine genetic and 
clinical evaluation, especially when the pathogenicity of the detected 
variant is uncertain, to evaluate the correlation between the genetic 
finding and clinical diagnosis for each family.83 If DNA is not available 
from the decedent and no clinical phenotype is present in the family, 
genetic testing of family members should be strongly discouraged.
3. Several studies have demonstrated that family screening should 
include at least a medical history, standard and high precordial 
lead ECG (to improve the detection of the Brugada syndrome), 
echocardiography, exercise test,80,81,143,144,334 and Holter moni-
toring on a case- by- case basis.
4. CMR and 24- hour ambulatory monitoring of family members can 
inform diagnosis.4,5
5. and 6. A careful assessment of the circumstances of sudden 
death may point to a specific diagnosis. Sudden death in a young 
or middle- aged male occurring during a febrile illness or sleep 
suggests the diagnosis of Brugada syndrome, whereas sudden 
death occurring in a subject during physical activity suggests the 
diagnosis of long QT syndrome or CPVT. As Brugada syndrome 
may be masked or intermittent in some patients, sodium channel 
blocker challenge may unmask the type 1 pattern and increase 
the effectiveness of family screening. It should be recognized 
that there is a potential high rate of false positives, as data on 
the specificity and sensitivity of the test are not available, and a 
positive ECG may be induced in 4%– 5% of normal subjects.286,361 
In the pediatric age group, a negative test may convert to a posi-
tive test after puberty.362 Long QT syndrome may also be un-
masked by standing, exercise test, epinephrine test, or mental 
stress test.266,269,270,275,288 In first- degree relatives of young SUD 
victims with no manifest abnormalities during the initial examina-
tion, the risk of developing manifest inherited cardiac disease or 
cardiac events during follow- up is low.205
9  | FUTURE DIREC TIONS
Many of the recommendations in this document seem intuitive, 
obvious, and straightforward; however, much of what is being 
recommended within this document is seldom routinely per-
formed even in well- resourced countries. Many decedents of 
SUD never receive an autopsy, and the evaluation of first- degree 
relatives of an SUD victim or an SCA survivor ranges widely from 
no evaluation to ordering a multitude of tests that are then re-
peated regularly and indefinitely. The extensive variability in 
practice indicates that developing common sense processes and 
multidisciplinary teams remains a considerable challenge in many 
areas and guidance is required. Developing these processes and 
teams involves leaders challenging many medico- political barriers 
that obstruct and delay best medical practice. We hope that this 
document will empower those who wish to achieve such changes 
for the better, including efforts for continuous improvement of 
practice. So, assuming the recommendations in this document are 
embraced and implemented, what are the next steps and future 
directions in this field?
Firstly, unlike cancer statistics and even SCD in the elderly due to 
coronary artery disease, the precise prevalence, epidemiology, and 
etiologies of either SUD or SCA in the young remain obscure in most 
countries. Only if these conditions become a notifiable event will the 
true scale and scope ever be captured.
Secondly, communities, states/provinces, and countries must 
advocate for and expect that a true comprehensive autopsy, in-
cluding postmortem genetic testing (ie, molecular autopsy), oc-
curs whenever an SUD occurs in a young person. The current 
dismal rate of autopsy must be reversed. Only when this be-
comes the standard of care will the true epidemiology/etiology 
of SCD be determined.
Thirdly, the basic occurrence and subsequent extent of an evalua-
tion of the living, whether she/he is an SCA survivor or the first- degree 
relative of an SUD victim or an SCA survivor, must become standard 
of care. After initial cardiological evaluation (examination, ECGs, stress 
test, and echocardiogram) has been completed, the true contribution of 
SCA- predisposing genetic heart disease will be exposed. Furthermore, 
the composition and contribution of advanced investigations ranging 
from sodium channel drug provocation studies, to MRI, to genetic 
testing requires further study, as does the recommended interval for a 
repeat cardiological evaluation of the first- degree relatives when their 
first evaluation is either normal or inconclusive.
Finally, when such investigations are commenced, future 
studies to minimize the collateral damage from uncertain clinical 
findings and genetic “variants of uncertain significance” will be 
needed. While it is recognized that the correct necropsy diagnosis 
of the SUD decedent and the correct diagnosis of the SCA survivor 
may give patients and their families some answers and resolution 
to the event, the premature and erroneous diagnosis due to ex-
cessive confidence in or overinterpretation of clinical or genetic 
findings of uncertain significance can cause remarkable harm. If 
we are to “first do no harm,” the model of multidisciplinary teams 
with the expertise to correctly evaluate all the investigations and 
potential (mis)diagnoses should be made accessible to all.
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